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I Introduction 1
I Introduction
I.1 Human cystatin C in health and disease
Mature human cystatin C (hCC) is a basic 13-kDa protein, composed of 120 amino acids in
one single polypeptide chain whose amino acid sequence was identified in 1982 (Grubb and
Löfberg 1982, Grubb et al. 1984). The hCC is synthesized as a precursor protein, containing a
26 amino acid long leader peptide, indicating a role in extracellular fluids (Abrahamson et al.
1987). In 1961, hCC was mentioned for the first time in literature where it was discovered as
urinary-protein in patients with clinical proteinuria, although named “post γ-protein” instead
of hCC (Butler and Flynn 1961). The first quantification of hCC in biological fluids occurred
in 1979. There the γ-trace (hCC) concentration in cerebrospinal fluid (CSF) and plasma
respectively was determined (Löfberg and Grubb 1979). The physiological range of hCC
concentration in serum including both genders was determined about 20 years later to
0.51-0.98 mg/l (Finney et al. 2000). After the determination of the hCC concentration in CSF
and plasma, its presence was found in different biological fluids, with especially high
concentrations in both, seminal fluid and CSF (Grubb et al. 1983). The physiological function
of hCC was identified in 1984, where hCC was initially shown to inhibit papain, cathepsin H,
B, L and ficin (Barrett et al. 1984, Brzin et al. 1984). The function of hCC as cysteine
protease inhibitor and its homology to cystatins from hen egg-white founded the name hCC,
which is used to date (Barrett et al. 1984).
The hCC has two disulphide bridge positions (73-83 and 97-117) of which at least one
was shown to be important for the inhibitory function (Grubb et al. 1984). The production of
native and biologically active hCC in E. coli enabled further functional analysis of hCC
(Abrahamson et al. 1988). The structure of monomeric and dimeric hCC (Figure 1) was
identified by crystallization of hCC (Ekiel and Abrahamson 1996, Ekiel et al. 1997).
Dimerization of hCC leads to a loss of biological activity (Ekiel and Abrahamson 1996). In
Chinese hamster ovary cells, transfected with a plasmid containing the hCC cDNA, hCC is
transported as inactive dimer through the cell and is activated upon secretion as monomer
(Merz et al. 1997). Nowadays it is known that hCC is produced by most nucleated cells
(reviewed in Grubb 2001).
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Figure 1: Structure of stabilized monomeric and wild-type dimeric hCC.
A β-sheet is wrapped around an α-helix of a stabilized monomeric hCC (A, PDB code: 3GAX) while on
dimerization of wild-type hCC (B and C, PDB code: 1G96) a 3D-dimensional domain swapping occurs were
most of the β-sheet from the first hCC is wrapped around the α-helix of the second (Kolodziejczyk et al. 2010).
α: α-helix, β: β-sheet, A-B: secondary structures marked in different colour, C: one colour for one hCC.
Historically hCC mainly was analysed in the context of disease. Therefore it was
discovered in patients with clinical proteinuria (Butler and Flynn 1961). Abnormalities in
hCC itself or the concentration of hCC were widely investigated. Often abnormal hCC
concentrations were found to be independently correlating in various human diseases (e.g.
neurodegenerative-, cardiovascular-, kidney disease, cancer and so on).
In the field of neurology hCC supports the differentiation of embryonic stem cells into
neuronal stem cells and has a neuroprotective action mediated by the mTOR pathway (Kato et
al. 2006, Kaur et al. 2010, Tizon et al. 2010a, Tizon et al. 2010b). However, a genetic
mutation in the hCC gene causes severe disease. In the Island type “hereditary cystatin C
amyloid angiopathy” a point mutation (L68Q) causes brain haemorrhage (Palsdottir et al.
1988, Olafsson and Grubb 2000). The amyloidogenic action of L68Q hCC occurs by three-
dimensional domain swapping, which leads to di- and oligomerisation, thereby forming
insoluble plaques (Janowski et al. 2001, Nilsson et al. 2004). Changes in lifestyle were shown
to drastically reduce the life span of patients carrying this mutation (Palsdottir et al. 2008). In
Alzheimer’s disease amyloid-β (Aβ) aggregation occurs. In the year 2000, polymorphism in
the hCC gene was identified and is associated to the late-onset of Alzheimer’s disease
(Crawford et al. 2000, Finckh et al. 2000). Although hCC inhibits the Aβ-aggregation in vitro
and in vivo, it does not dissolve preformed aggregations (Tizon et al. 2010a), which
underlines the regulatory importance of hCC. In patients with multiple sclerosis, as well as in
those having amyotrophic lateral sclerosis, the hCC concentration in CSF was found to be
reduced in comparison to healthy individuals which is why it was suggested as specific
biological marker for both diseases (Bollengier 1987, Wilson et al. 2010).
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The hCC was also shown to correlate to different cancer types. In the human male
reproductive system hCC is highly expressed (Jiborn et al. 2004), whereas it is downregulated
in prostate cancer (Wegiel et al. 2009). In contrast, the upregulation of hCC was indicated by
immunostaining in esophageal cancer (Zeng et al. 2011). In breast cancer, the transforming
growth factor β (TGF-β) promotes metastasis by the upregulation of miR-181a (Taylor et al.
2013). Already in 2005, without this knowledge, the promotion of metastasis was shown to be
prevented by hCC treatment (Sokol et al. 2005). A few years later, hCC was shown to be an
antagonist of TGF-β (Tian and Schiemann 2009), thereby revealing a function of hCC beyond
its action as protease inhibitor. A study on the uptake of hCC and an hCC mutant into MCF-7
cells uncovered the W106F-mutant to be best taken up. Thus the W106F-mutant was
suggested as protein variant to control protease-promoted cancer progression (Wallin et al.
2013). Upon chemotherapy serum hCC levels may increase and caution with the used of hCC
as biomarker for the determination of the estimated glomerular filtration rate (eGFR) is
advised (Yamawaki et al. 2013).
In other clinical studies the hCC concentration was investigated as well and often
suggested as endogenic marker for diagnosis. In women of reproductive age, a higher hCC
concentration in serum was correlated to polycystic ovary syndrome, a most common
endocrine disorders (Gozashti et al. 2013).
Although some work indicates an association of elevated hCC levels in diabetes, it
could not be excluded that the onset of chronic kidney disease (CKD) may interfere or even
cause the increase (Sahakyan et al. 2011). Additionally, in a diabetic Chinese population a
strong correlation between an elevated hCC level and limp arterial disease was found (Liu et
al. 2013). Therefore, cardiovascualar disease may also cause misleading results on diabetes.
The hCC itself is freely filtrated by glomerular filtration and is reabsorbed by the
proximal tubules (Thakkar et al. 1998), where it is degraded (Jacobsson et al. 1995). Already
in 1985, the serum concentration of hCC was proposed as a marker to estimate the eGFR that
reflects kidney health (Simonsen et al. 1985). Although creatinine is more often used in
clinical diagnostics, hCC was proposed to be a more accurate marker, because creatinine
depends on height, gender, age and muscle mass (Filler et al. 2005). However, it is now
known that hCC is also a not completely independent diagnostic marker (Guerre-Millo 2012).
Several equations have been developed to overcome limitations caused by the dependencies
of hCC and creatinine (Levey et al. 2014). Whether the hCC-based eGFR or the creatinine-
based eGFR is best for accurate determination of the eGFR is contentious, and seems to
depend of the type of disease (Shlipak et al. 2005, Bhasin et al. 2013, Hamed et al. 2013,
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Rule et al. 2013, Ataei et al. 2014, Delanaye et al. 2014). In chronic kidney disease an eGFR
based on both biomarkers, hCC and creatinine, was recently shown to be superior to the single
marker-based eGFR (Inker et al. 2012).
The serum hCC concentration is also correlating in several subtypes of cardiovascular
diseases. An increased hCC level is associated with arterial stiffness in older adults and with
inducible ischaemia among patients with stable coronary disease (Deo et al. 2009, Madero et
al. 2009). Moreover, an elevated hCC level predicts long-term mortality in patients with
peripheral arterial disease (Urbonaviciene et al. 2011). In high-risk cohort patients,
undergoing coronary angiography, the use of hCC among two other markers helps to
reclassify and discriminate risk and predicts mortality (Nead et al. 2013). In women an
elevated hCC level is a risk factor for all-cause mortality (Toft et al. 2012). Furthermore, the
sudden cardiac death risk in elderly is independently associated to impaired kidney function,
estimated by measurement of hCC but not creatinine (Deo et al. 2010). Therefore instead of
creatinine, hCC was suggested as marker for the prediction of mortality and cardiovascular
events in patients with chronic kidney disease (Vigil et al. 2014).
I.2 Former and current hCC diagnostic assays
The quantification of hCC was an issue to science from the eighties on. Löfberg and Grubb
gave the starting signal for the development of accurate and sensitive assays for the
determination of hCC, others followed and took the challenge (Löfberg and Grubb 1979).
First, the focus was laid on the development of sensitive hCC-specific assays. Later, beside
sensitivity, the safety and the time consumption of an assay became the main focus of interest.
Over time, hCC-specific assays were further developed for laboratory and clinical use, also
partially reviewed by Mussap and Plebani (Mussap and Plebani 2004).
In 1979, the first quantitative determination of hCC in biological fluids was established
by enzyme-amplified single radial immunodiffusion (EA-SRID) and by competitive enzyme
immunoassay (EIA) (Löfberg and Grubb 1979). Therefore urinary-hCC of human origin was
used to generate hCC specific polyclonal rabbit antiserum. The obtained sensitivities differed
from one to the other by ten-fold, 300 ng/ml for EA-SRID and 30 ng/ml for EIA. Four years
later, the hCC content was determined by radioimmunoassay (RIA) using polyclonal rabbit
antibodies (Poulik et al. 1983). The sensitivity obtained was 0.1 ng/ml, which is a 24-fold
improvement in sensitivity in comparison to EIA. Although radiolabels offer high sensitivity,
the hazards and risks of radiolabelled material are unwanted and were avoided three years
later by time-resolved fluorescence immunoassay (TR-FIA) using a non-radioactive label
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which enabled the observation over time (Joronen et al. 1986). The obtained sensitivity using
polyclonal rabbit antibodies was eight-fold lower (1 ng/ml) than that published for RIA. The
enzyme-linked immunosorbent assay (ELISA), using a sandwich approach, was carried out
for the determination of hCC in 1989, where hCC-specific polyclonal rabbit-antibodies were
used for the capture of hCC but hCC-specific monoclonal murine anticodies for the detection
in combination with murine-specific peroxidase-labelled antibodies (Ishiguro et al. 1989).
Thereby, they achieved a sensitivity of 1.9 ng/ml which is comparable to the one determined
by Joronen et al. using TR-FIA (Joronen et al. 1986). Additionally it was the first report in
which the association constants for hCC-specific monoclonal murine-antibodies using RIA
according to Frankel and Gerhard was obtained which ranged from 3.6 x 109 M-1 to
7.3 x 1010 M-1 (Frankel and Gerhard 1979). No dissociation constants were determined.
A further advanced ELISA was published in 1992 (Collé et al. 1992) in which purified
hCC-specific polyclonal goat-antibodies were used as both, unlabelled capture antibodies and
biotinylated secondary antibodies for further detection with horse radish peroxidase (HRP)-
avidin. A comparable sensitivity to the RIA (Poulik et al. 1983) was achieved again
(0.19 ng/ml) making the usage of radioactive probes now completely unnecessary. This high
sensitivity became possible by the use of biotin-strepavidin whose interaction is known to be
the strongest naturally occurring with an association constant of 1015. Therefore it can be used
to enhance sensitivity of assays (Nerurkar 1984). One year later the ELISA was optimized in
terms of assay duration by using commercially availible hCC-specific polyclonal rabbit-
antibodies, where one part was directly coupled to HRP. The time needed for one assay could
thereby be reduced to 2 h, while still obtaining a sensitivity of 0.9 ng/ml (Pergande and Jung
1993).
In 1994, the first automated assay for the determination of hCC in serum samples,
suitible for clinical application, was presented. With a throughput of 90 samples per hour and
a 7-min analysis for urgent samples the automated particle-enhanced turbidimetric
immunoassay (PETIA) was established (Kyhse-Andersen et al. 1994). The PETIA is based on
agglutination of hCC using immunoparticles which consists of polyclonal rabbit antibodies
coupled to 38-nm carboxylate-modified latex particles. Thereby an assay range of 0.4-
14.1 μg/ml was shown on a Cobas Fara instrument (automated single-unit centrifugal
analyser, F. Hoffmann-La Roche, Basel, Switzerland). One year later Newman et al.
optimized the PETIA for its use in all clinical analysers, which are generally used for the
determination of creatinine, thereby enabling a broad clinical determination of the hCC
concentration for eGFR. For this approach, 77-nm latex particles and a Monarch 2000
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centrifugal analyzer (Instrumentation Laboratory, Warrington UK) were used (Newman et al.
1995). In contrast to the PETIA using a turbidimetric analyser, the particle-enhanced
nephelometric immunoassay (PENIA) was described for nephelometers, using 80-nm
chloromethyl styrene particles, with a sensitivity of 0.2-7.3 μg/ml and a reduction of time by
one minute per sample (Finney et al. 1997). In 2004, another fully automated assay, the sol
particle immunoassay (SPIA), for the measurement of hCC in serum was published (Tanaka
et al. 2004) using colloidal gold particles coated with hCC-specific rabbit antibodies to
reproducibly detect hCC with high linearity from 0.2 μg/ml to 8 μg/ml.
In 2010, an hCC-specific dry-reagent double-monoclonal assay was published, showing
that the scientific interest in hCC still requires the optimization of hCC specific assays
regarding the assay-duration and simplicity of procedure (Ristiniemi et al. 2010). In 2012,
Ristiniemi et al. developed an hCC-specific TR-FIA-based quantification method reducing
the assay duration to 10 minutes (Ristiniemi et al. 2012). The development of a variety of
assays for the determination of hCC assays increased the necessity for assay standardization
(Voskoboev et al. 2011).
Although the assays summarized seem to be very diverse, they all have one feature in
common: all assays are developed for ex vivo application. Until now there are no diagnostic
systems available for the in vivo quantification of hCC in the human blood stream. However,
there is a medical segment which uses in vivo detection for diagnosis.
I.3 Therapeutic implants and “Home monitoring systems”
In the area of cardiovascular disease therapeutic implants are found which additionally are
used for diagnosis. In cardiovascular diseases patients can be treated according to their
incidences with implants, like pacemakers, defibrillators and systems for a cardiologic
resynchronization therapy respectively. These implants are nowadays collecting diagnostic,
therapeutic and technical data that are transmitted to external devices. The use of so called
“Home monitoring” systems enables the supervision and recording of parameters, as well as
automated global supervision and treatment of patients (Biotronik, St. Jude Medical,
Medtronic). The area of healthcare by monitoring with a wearable and implantable wireless
sensor network solution is enlightened in more detail in the review by Darwish et al. (Darwish
and Hassanien 2011).
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I.4 Implantable diagnostic devices, sensors and biosensors
In the field of diagnostics, sensors or chips emerged and are further developed to give highly-
specific and sensitive diagnostic devices. In this field, sensors, biosensors and immunosensors
are found. The term sensor is mainly used for devices without biological components. The
acronym containing “bio” is generally used when biological components, which may belong
to several biological molecules like DNA, RNA and proteins, are incorporated into the
detection device (Ge et al. 2014). A subgroup of biochips or biosensors is represented by
immunochips or immunosensors, which use antibodies as biological component of the device
itself. Ngoepe et al. categorized the transduction signal used for sensors into the four
following groups, optical, electrochemical, thermal and mass sensitive (Ngoepe et al. 2013).
More recently, the acoustic transduction was added as fifth group (Chang et al. 2014).
Implanted sensors are rarely found. For monitoring of cardiovascular systems
implantable sensors have been applied and suggested as diagnostic mean by which the
patient’s heath state can be monitored without interrupting the daily life (Tan et al. 2008). In
this article the authors present an implantable sensor specific for strain and pressure without
the involvement biological components in the sensor itself. The sensor is based on magnetic
elements which depending on the pressure are differently distanced from each other, thereby
inducing a magnetic harmonic field. However, the sensor has not been implanted in this study.
Ohta et al. reviewed their own work on CMOS-based chip sensors for retina prosthesis and
deep brain monitoring; a device that was truly implanted (Ohta et al. 2009). This sensor is
equipped with an enhanced green fluorescent protein (GFP)-filter and monitors the presence
of a fluorescent product which is generated upon substrate cleavage by serine protease,
thereby monitoring its activity. However, retinal implants are an issue to science since a long
time (Nadig 1999). Issues like biocompatibility, power supply, bio fouling and many more
have to be considered for the development of an implantable diagnostic device. Recently, an
implant-trial for wireless blood-pressure-monitoring-sensors in sheep was published showing
functionality over six months and good performance as no thrombi, necrosis and apoptosis
respectively were found (Cleven et al. 2014). Another example for implantable sensors is
given by Hou et al. in the field of oxygen measurement (Hou et al. 2014).
Ngoepe et al. reviewed integrated biosensors in diagnostics and drug delivery system as
well as the considerations accompanying the development of integrated biosensors. An
example for an integrated biosensor was published in 2013 (Secchi et al. 2013). The biosensor
developed for the ethanol quantification in the brain, using the enzyme “alcohol oxidase” as
biological component, was investigated for its in vitro stability, revealing a proper working
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period of one week only. The small number of functional fully-integrated sensors, mainly
sensors or biosensors but not immunosensors, shows that a lot of work has still to be done in
this field.
For immunosensors many different designs, setups and principles have been applied so
far. Immunosensors are mainly developed for clinical applications. However, one exception
was published by the Italian group around Battari et al. which developed a nanostructured
electrochemical biosensor for the analysis of tempera paintings for their content of hen's egg
yolk (Bottari et al. 2014).
For clinical applications several immunosensors have been developed for the detection
of classical cancer biomarkers like carcinoembryonic antigen (CEA), human epidermal
growth factor receptor (HER) and prostate specific antigen (PSA). Akter et al. present a CEA-
specific sensor which functions by electrocatalyzed oxidation. There free CEA competes with
a magnetic beat-supported 3,3′,5,5′-tetramethylbenzidine-conjugated CEA, which is
electrochemically labelled, for the binding to an α-CEA antibody, thereby reducing the
catalysed oxidation (Akter et al. 2014). Lu et al. developed a low-cost label-free
amperometric sensor which uses infinite coordination polymer fibre to which gold
nanoparticle are attached by thionine. This sensor displays a high sensitivity and a linear
range of 50 fg/ml to 100 ng/ml and a detection limit as low as ~0.5 fg/ml CEA (Lu et al.
2014). Another CEA-specific sensor, using an electrochemical readout, is based on a
sandwich assay where a CEA-specific antibody is immobilized to hyperbranched structures
and the secondary HRP-labelled antibody is bound to gold nanoparticles (Miao et al. 2014).
Chen et al. published an electrochemiluminescence immunosensor for CEA which uses two-
dimensional graphite-like carbon nitride nano-sheets that were hybridized with gold
nanoparticles, thus yielding a linear range of 0.02 ng/ml to 80 ng/ml and a detection limit of
6.8 pg/ml (Chen et al. 2014). Beside CEA, immunosensors were successfully developed for
other cancer biomarkers. The disposable immunosensor for HER uses electrochemical
impedance spectroscopy for the quantitative detection with an incredibly high sensitivity and
a linear range from 2 fg/ml to 14 fg/ml (Asav and Sezginturk 2014). An immunosensor for the
detection of HER-2 is based on polyethylene glycol treated-iron oxide nanoparticle on which
α-HER-2 antibodies are immobilized for electrochemical detection reaching a sensitivity in
the ng/ml-range (Emami et al. 2014). Another disposable immunosensor, this time for the
detection of HER-3, uses indium tin oxide substrates on which α-HER-3 is immobilized. The
evaluation occurs on the bases of charge transfer resistance by electrochemical impedance
spectroscopy. In this way, very high sensitivity and a linear range from 40 fg/ml to 200 fg/ml
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is shown for the antigen (Canbaz and Sezginturk 2014). The last immunosensor for the
detection of classical cancer biomarker in this chapter is specific for PSA and is based on
copper monosulphide nanoparticles which enable the oxidation of a non-fluorescent substrate
to the fluorescent product (Zhu et al. 2014).
Additionally, immunosensors have been developed for the detection of cancer
associated biomarkers like the calmodulin (CaM) and 8-hydroxy-2′-deoxyguanosine
(8OHdG). The former is associated with cancer progression, while the latter is a marker for
oxidative stress, which is associated with chronic diseases and cancer. For the CaM-specific
sandwich-like immunosensor two HRP enzyme-layers were applied for amplification. Using
the electrochemical readout a linear range from 5.0 pg/ml to 100 ng/ml was published (Fu et
al. 2014). Ferreira et al. used orientated immobilization of 8OHdG-specific antibodies to a
gold surface only. Here the evaluation is also based on the charge transfer resistance (Ferreira
and Sales 2014).
Immunosensors specific for non-cancer biomarkers are mainly based on optical
detection. Pieres et al. presents an optical immunosensor specific for human salivary cortisol,
which is associated to stress-related diseases. A sandwich assay leads to the increase of
chemiluminescence upon antigen binding which is based on amperometric detection by
organic photodiodes. Thus a linear range from 0.1 ng/ml to 175 ng/ml is achieved (Pires and
Dong 2014). Joung et al. developed a C-reactive protein specific optical immunosensor which
manages fluidic issues avoiding the use of complicated and cost intensive microfluidics. The
assay is based on chemiluminescent lateral flow which, by the delayed-release of the substrate
and the special arrangement of the detection antibodies, establishes the functionality of the
immunosensor (Joung et al. 2014). Beside the optical systems, one research group presents an
acoustic-immunosensor, using piezo crystals, for drug monitoring in whole blood samples
with a linear range from 1 ng/ml to 1000 ng/ml (Chang et al. 2014).
All summarized immunosensors show the large variety in usable detection principles to
ensure the specific and highly sensitive detection of biomarkers. However, the
immunosensors are mainly designed for in vitro and rarely for in vivo detection. Hence, the
development of a hCC-specific and reversible bioassay for the later on integration into an
implantable biochip system is the subject of this PhD thesis.
I.5 DiaImplant and the predicted hCC-specific detection principle
The project “DiaImplant” was initiated in order to add diagnostic functions to implants for in
vivo monitoring of biomarkers. This is a highly active scientific field and of interest since
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diagnostic implants may one day facilitate the continuous observation of biomarkers in
chronic diseases (e.g. diabetes) and may serve as parameter for regulated therapeutic
intervention (Skjaervold et al. 2013).
One part of DiaImplant focused on the development of an hCC-specific diagnostic
implant which should be able to continuously quantify the hCC concentration in the human
blood stream. The project involved collaborations with the “Fraunhofer Institute for
Microelectronic Circuits and Systems” (Fraunhofer IMS, Duisburg), the “University of
Freiburg, Department of Microsystems Engineering” (IMTEK, Freiburg im Breisgau), the
“BIOTRONIK SE & Co. KG” (Biotronik, Berlin) and the “Fraunhofer Institute for Molecular
Biology and Applied Ecology IME” (Fraunhofer IME, Aachen). Within the project the
allocation of responsibilities were subdivided into the development of the chip-based
detection system (Fraunhofer IMS), the development of the hCC-specific and antibody-based
bioassay (Fraunhofer IME), the integration of the bioassay into the chip-based detection
system (IMTEK) and the project coordination as well as the animal experiments (Biotronik).
Although standard immunoassays for laboratory use were mainly optical-based (e.g. ELISA,
FIA), an electrical-based detection principle was favoured at the beginning of the project.
Decisive considerations were the avoidance of substrate-use for continuous measurement, the
energy consumption which would have been larger for former fluorescence-based detection
technologies and the possibility for miniaturization of the detection system. These
considerations match the recent immunosensor development (I.4) where most of the
immunosensors are based on voltametric and amperometric detection, respectively.
For the continuous monitoring of the hCC concentration by an implant it is very
important to enable the repetitive determination of the hCC concentration without the
intervention from outside, e.g. the exchange of antibodies or the application of striping steps.
Thus the predicted bioassay should be based on a reversible assay which allows the repetitive
and concentration-dependant replacement between two proteins of different electrical charges
on an hCC-specific antibody layer. One protein is the basic and to be analysed hCC, while the
other is an hCC-containing fusion protein whose fusion partner is of acidic protein nature or
in some way enables the shift of protein charge (Figure 2).
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Figure 2: Schematic illustration of the in vivo detection principle for the biochip.
The schematic depiction shows the antibody layer on the biochip with the fusion protein bound to the antibody in
the absence of hCC in solution (left). Upon addition of hCC the hCC-fusion protein should be replaced
according to the concentration of soluble hCC (right). At physiological pH value there is a difference in charge
between the fusion protein and hCC which should facilitate the discrimination of the hCC from the fusion
protein.
The association of charged proteins to the hCC-specific antibody layer should generate
an electric field at the chip surface, the extended gate of a metal oxide semiconductor
field-effect transistor (MOS-FET)-based detection system. The MOS-FET-based detection
system was predicted to fulfil the requirements regarding the system integration and the
measurement of the hCC-specific bioassay. The generated electric field at the extended gate
should change the gate potential which induces the change of resistance within the
drain-source connection thus changing the drain-source potential, the electrical measure.
I.6 Aim of this PhD thesis
The serum concentration of hCC is related to the GFR and beyond to cardiovascular diseases.
This correlation allows the classification of risk and the supervision of patient’s health. In
future, patient’s health, especially of those being treated with therapeutic implants in
cardiovascular diseases, could be monitored by additional diagnostic implants.
The aim of this PhD thesis is to develop an hCC-specific bioassay which is based on the
concentration-dependant replacement between hCC and an hCC-fusion protein on an
hCC-specific antibody layer thus enabling the repetitive determination of the hCC
concentration. The required hCC-specific antibody should have characteristics which differ
antibody
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-
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+
+
+
+
++
+
+
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from those of commercially available antibodies. The sought after hCC-specific antibody
should maintain its specificity for hCC while showing a reduced affinity to enable the
concentration-dependant replacement of hCC by the hCC-fusion protein and vice versa.
To fulfil the requirements of the presented detection principle hCC and hCC-fusion
proteins should be produced, purified and used for generation of hCC-specific antibodies. The
hybridoma technology should be subsequently used for the immortalization of murine B-cells
to enable the establishment and selection of monoclonal hybridoma cell lines producing hCC-
specific antibodies. Those antibodies should be produced, purified and provided for further
analysis. Purified monoclonal hCC-specific antibodies should be selected for their hCC and
hCC-fusion protein association and dissociation characteristics in terms of speed and the
similarity in kinetics. Thereby a combination of antigens and an antibody should be identified
which might enable replacement. Beyond, the implant compatibility of the selected hCC-
specific antibody should be verified. Finally, the identified potential combination of antigens
and an antibody should be analysed for its replacement functionality, its compatibility with
physiological and pathological hCC concentrations and its functionality in the predicted chip-
based detection system (Figure 3).
Figure 3: Workflow of this PhD thesis.
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II Material and methods
II.1 Material
II.1.1 Chemicals and consumables
Chemicals were purchased from Enzo Life Sciences (Lörrach), Roche (Karlsruhe), Sigma-
Aldrich (Taufkirchen). Consumabales were obtained from antibodies-online GmbH (Aachen),
B.Braun Melsungen AG (Melsungen), Bioline (Luckenwalde), Bio-Rad (München), Carl-
Roth (Karlsruhe), Dianova (Hamburg), Eurofins MWG Operon (Wieblingen), GERBU
Biotechnik GmbH (Heidelberg), Greiner Bio One (Frickenhausen), IBS INTEGRA
Biosciences GmbH (Fernwald), Institute for Reference Materials and Measurements (IRMM,
Geel, Belgium), Labomedic (Bonn), Life Technologies GmbH (Darmstadt), Macherey-Nagel
(Düren), Merck Millipore [former Biochrome] (Berlin), New England Biolabs (Frankfurt am
Main), Qiagen (Hilden), Santa Cruz Biotechnologies, Inc. (Heidelberg), SARSTEDT AG &
Co. (Nümbrecht), Sartorius Stedim (Goettingen), Thermo Fisher Scientific (Rockford, IL,
USA), VWR (Langenfeld).
Cell culture media, buffers and additives were purchased from Merck Millipore [former
Biochrome] (Berlin) and Life Technologies GmbH (Darmstadt).
The standard serum for hCC was obtained from IRMM (Geel, Belgium).
II.1.2 Enzymes, reaction kits and matrices
The enzymes, reaction kits and matrices for purification used in this PhD thesis are
summarized in Table 1, Table 2 and Table 3.
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Table 1: Used enzymes with the appropriate suppliers.
Enzymes Suppliers
Taq DNA polymerase Fraunhofer IME and Invitrogen
Phusion High-Fidelity DNA Polymerase Thermo Scientific
TrypLE™ Express Invitrogen
All restriction enzymes and the appropriate buffers NEB
Antarctic Phosphatase and the appropriate buffer NEB
T4 DNA Ligase and the appropriate buffer NEB
Table 2: Used reaction kits with the appropriate suppliers.
Kits Suppliers
NucleoSpin® Plasmid Macherey-Nagel
NucleoSpin® Extract II Macherey-Nagel
NucleoSpin® Gel and PCR Clean-up Macherey-Nagel
Pierce® BCA Protein Assay Kit Thermo Scientific
Mouse Immunoglobulin Isotyping ELISA Kit BD Biosciences
NucleoSpin® RNA Macherey-Nagel
SuperScript® III Fist-Strand Synthesis System for RT-PCR Invitrogen
Table 3: Used matrices for protein purification with the appropriate suppliers.
Matrices Suppliers
Ni-NTA Superflow Qiagen
Glutathione HiCap matrix Qiagen
Protein A Ceramic HyperD F Pall
Protein G Agarose KPL
Q Ceramic HyperD F Pall
II.1.3 Oligonucleotides and plasmids
All oligonucleotides were ordered at MWG Eurofins. The oligonucleotides and originating
plasmids are summarized in Table 4 and Table 5.
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Table 4: Used oligonucleotides and their applications.
Oligonucleotides Sequences (5’->3’) Applications
5’ GST GGA AAC AGT ATT CAT GTC CCC TAT
ACT AGG
Cloning of GST-hCC by SOE-
PCR
3’ GST GAG GTT TGC CAG GGC TGG ATT TTG
GAG GAT GGT C
5’ hCC(GST) GAC CAT CCT CCA AAA TCC AGC CCT
GGC AAA CCT C
3’ Igκ GTT TGC CAG GGC TGG AAC CAG TGG
AAC C
Cloning of Igκ-hCC by SOE
PCR
5’ Igκ GAG CAG CTA GCA TGG AGA CAG ACA
CAC TCC TGC TAT G
5’ Igκ-hCC CAG GTT CCA CTG GTT CCA GCC CTG
GCA AAC
5’ NheI natlnt TAC GCT AGC ATG GCC GGC CCT CTG
5’ Sfi-hCC ATA GGC CCA GCC GGC CTC CAG CCC
TGG CAA ACC TC
3’-HCC TGA ATA TGC GGC CGC GGC ATC CTG
ACA GGT GG
Cloning of GST-hCC and Igκ-
hCC by SOE PCR
5’ pMS-CMV-
forward
GGC AGT ACA TCA AGT GTA TCA TAT
GCC
Sequencing primers for the
pMS plasmid
3’ Hinter-his-
reverse
CCA ACA GCT GGC CCT CGC AGA CAG
pGEXbackw CCG GGA GCT GCA TGT GTC AGA GG Sequencing primers for the
pGEX5x3 plasmidpGEXforw GGG CTG GCA AGC CAC GTT TGG TG
Table 5: Used originating plasmids with the appropriate suppliers.
Plasmids Suppliers
pET26b(+) Novagen
pCR2.1-hcystatin Eurofins MWG operon
pGEX5x3-E2(1b) Dr. Christiane Püttmann
pMS-LH22-IV Katharina Kolberg born Ranft
pMS-EGFRex-Hinge-Fc Dr. Christoph Stein
pUC19c Roth
The pMS-plasmids are based on the commercially available pSec-Tag2-plasmid (Invitrogen,
USA) and were generated by modification (Stoecker et al. 2003).
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II.1.4 Antibodies and substrates
Table 6: Used antibodies with the appropriate suppliers, the antibody working -/stock concentration and
their applications.
Abbreviation Antibody Suppliers Working concentration
(concentration of stock
solution)
Applications
α-HIS Mouse α-polyHistidine
(mouse IgG2a)
Sigma 0.44 µg/ml (2.2 mg/ml) Immunoblot
Cyst-13 Mouse α-Cystatin IgG1 HyTest 0.68 µg/ml (3.4 mg/ml) Immunoblot
GAH Goat α-human IgG Thermo
Scientific
0.80 µg/ml (4.0 mg/ml) ELISA
GAMAP(Fc) Goat α-mouse IgG
(Fc specific)AP
Sigma 0.26 µg/ml (1.3 mg/ml) Immunoblot
GAMAP(H+L) Goat α-mouse IgG
(H+L)AP
Dianova 0.12 µg/ml (0.6 mg/ml) Immunoblot
GAMHRP (Fc) Goat α-mouse IgG
(Fc specific)HRP
Sigma 1.74 µg/ml (8.7 mg/ml) ELISA,
Immunoblot
AP=alkaline phosphatase
HRP=horse radish peroxidase
Table 7: Used substrates with the appropriate suppliers and the substrate application.
Substrates Suppliers Applications
NBT/BCIP Carl-Roth Immunoblot
ABTS Roche ELISA
SIGMAFAST™ DAB Sigma Immunoblot
NBT/BCIP=nitro-blue tetrazolium and 5-bromo-4-chloro-3’-indolyphosphate
ABTS=2,2’-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid)
DAB= 3,3′-Diaminobenzidine
II.1.5 Buffers, media and solutions
All standard media, solutions and buffers were prepared according to Sambrook (Sambrook
and Russell 2001) with deionized water unless otherwise stated. Media and agar were
autoclaved at 121°C and 1 bar for 20 min. Thermo-instable solutions were sterilized by
0.22-µm filtration.
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Table 8: Composition of used media, buffers and solutions.
Media/Buffer/Solution Components Concentration
AEX buffer 1 (Anion exchange
chromatography, pH 9.0)
ethanolamine 20 mM
NaCl 30 mM
AEX buffer 2 (Anion exchange
chromatography, pH 9.0)
ethanolamine 20 mM
NaCl 1 M
AP buffer (pH 9.6) Tris-HCl 100 mM
NaCl 100 mM
MgCl2 5 mM
BCIP BCIP 5% (w/v)
Dimethylformamide (100%) 95% (v/v)
Biotinylation buffer A (pH 5.5) sodium acetate 0.1 M
Biotinylation buffer B Biotinylation buffer 1x
Sodium meta-periodate solution 20 mM
Biotinylation buffer C Biotin LC hydrazide 50 mM
DMSO 1x
Blotting buffer (pH 8.3 not
adjusted)
Tris 25 mM
Glycine 192 mM
Methanol 20% (v/v)
1% BSA (Blocking solution) Bovine serum albumin 1% (w/v)
PBS 1x
2x Coating buffer, pH9.6 Na2CO3 0.2 M
NaHCO3 0.2 M
Coomassie staining solution Coomassie Brilliant Blue G-250 0.25% (w/v)
Methanol 50% (v/v)
Glacial acetic acid 9% (v/v)
Coomassie destaining solution Methanol 10% (v/v)
Glacial acetic acid 10% (v/v)
dNTP mixture dATP 10 mM
dCTP 10 mM
dGTP 10 mM
dTTP 10 mM
Freezing medium RPMI 1640 Medium, GlutaMAX™ Supplement 70% (v/v)
FCS (fetal calf serum) 20% (v/v)
DMSO 10% (v/v)
Glycine buffer (pH 2.9) Glycine 0.2 M
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10x IMAC-BW buffer (Ni-NTA
purification, pH 8.0)
Na2HPO4 0.5 M
NaCl 3 M
Imidazole 0.1 M
IMAC-BW buffer (Ni-NTA
purification, pH 8.0)
Na2HPO4 50 mM
NaCl 300 mM
Imidazole 10 mM
IMAC elution buffer (Ni-NTA
purification, pH 8.0)
Na2HPO4 50 mM
NaCl 300 mM
Imidazole 250 mM
LB (pH 7.4) NaCl 1.0% (w/v)
Peptone 1.0% (w/v)
Yeast extract 0.5% (w/v)
NBT NBT 10% (w/v)
Dimethylformamide (70% (v/v)) 90% (v/v)
NBT/BCIP BCIP 50% (v/v)
NBT 50% (v/v)
NHS buffer A (pH 8.3) NaHCO3 0.2 M
NaCl 0.5 M
NHS buffer B HCl (ice cold!) 1 mM
NHS buffer C (pH 8.5) Tris-HCl 0.1 M
NHS buffer D (pH 4.0) acetate 0.1 M
NaCl 0.5 M
10x PBS NaCl 1.37 M
KCl 27 mM
Na2HPO4 92 mM
KH2PO4 15 mM
PBS (pH 7.4) NaCl 137 mM
KCl 2.7 mM
Na2HPO4 9.2 mM
KH2PO4 1.5 mM
PBS-EW (GST-based
purification, elution /wash
buffer, pH 7.2)
PBS-GST 1x
DTT 1 mM
EDTA 1 mM
PBS-GST (GST-based
purification, pH 7.2)
NaH2PO4 50 mM
NaCl 150 mM
II Material and methods 19
PBS-L (GST-based purification,
lysis buffer, pH 7.2)
PBS-GST 1x
Protease inhibitors tablet cOmplete, EDTA-free one for 50 ml
DTT 1 mM
EDTA 1 mM
Triton X-100 1% (v/v)
Lysozyme 1 mg/ml
PBST (pH 7.4) PBS 1x
Tween 20 0.05% (v/v)
Protein A storage buffer Ethanol 20% (v/v)
NaCl 1.5 M
4x Protein A bining buffer (pH
8.0)
Tris-HCl 1 M
1x Protein A binding buffer (pH
8.0)
Tris-HCl 250 mM
Protein A elution buffer (pH
2.5)
Trisodium citrate 0.2 M
Protein A neutralization buffer
(pH 9.0)
Tris-HCl 1 M
5x Protein loading buffer
(reducing)
Tris-HCl (pH 6.8) 62.5 mM
Glycerol 30% (v/v)
SDS 4% (w/v)
Bromphenol blue 0.05% (w/v)
β-Mercaptoethanol 10% (v/v)
R10 (Cell culture medium) RPMI 1640 Medium, GlutaMAX™ Supplement 90%(v/v)
FCS (fetal calf serum) 9% (v/v)
Penicillin-Streptomycin (10,000 µg/ml each) 0,9% (v/v)
TAE buffer Tris 40 mM
Glacial acetic acid 5.7% (v/v)
EDTA 10 mM
TGS buffer Tris 25 mM
Glycine 192 mM
SDS 0.1% (w/v)
TNGT (GST-based purification,
pH 8.0)
Tris 50 mM
NaCl 0.4 M
L-Glutathione reduced 50 mM
DTT 1 mM
Triton X-100 0.1% (v/v)
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II.1.6 Bacterial strains
Plasmid DNA was amplified using the Hanahan’s bacterial strain Escherichia coli (E. coli)
DH5α (Invitrogen). The strains genotype is the following: F– Φ80lacZΔM15 Δ(lacZYA-argF)
U169 recA1 endA1 hsdR17 (rK–, mK+) phoA supE44 λ– thi-1 gyrA96 relA1 (Invitrogen).
Protein expression was performed with the bacterial stain E. coli BL21 (genotype F– ompT
hsdSB(rB– mB–) gal dcm (DE3)) (Novagen).
II.1.7 Cell lines
Proteins were transiently produced in the eukaryotic system using the human embryonic
kidney cell line 293 which is established by transfection with “sheared DNA of adenovirus
type 5 (HEK293T, ACC 635, Leibniz Institute DSMZ-German Collection of microorganisms
and Cell cultures, DSMZ, Braunschweig, Germany) (Graham et al. 1977). The cell line used
for the generation of hybridomas was SP2/0-AG14 (ACC 146, DSMZ, Braunschweig,
Germany) (Shulman et al. 1978).
II.1.8 Animals
Female white 6-8 weeks old BALB/c mice were used for the generation of antibodies by
immunization (Taconic, Cologne).
II.1.9 Permission for recombinant DNA work
The S1-permission for the genetic facility and the recombinant DNA work is registered at the
“Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen (LANUV
NRW)” with the reference file number 64-K-1.19/01.
II.1.10 Permission of animal experiments
Animal experiments were officially approved by the Landesamt für Natur, Umwelt und
Verbraucherschutz Nordrhein-Westfalen (LANUV NRW), reference number 84-
02.05.30.12.097. All animals received humane care in accordance with the requirements of
the German Tierschutzgesetz, §8 Abs. 1 and in accordance with the Guide for the Care and
Use of Laboratory Animals published by the National Institute of Health.
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II.1.11 Equipment and software
Autoclave Varioclav H+P 135S (H+P Labortechnik GmbH,
Oberschleißheim)
Systec HX-430 (Systec, Wettenberg)
Centrifuges Avanti J25 I (Beckmann Coulter, Krefeld)
Multifuge1s/-3s-R, Biofuge PrimoR (Heraeus Holding GmbH,
Hanau)
Centrifuge 5415D, Centrifuge 5415R (Eppendorf, Hamburg)
Microfuge (Roth, Karlsruhe)
Rotina 420R (Hettich, Tuttlingen)
CO2 incubator Heracell™ B12 (Thermo Scientific)
Electrophorese apparatus Mini-PROTEAN 3 Electrophoresis System, PowerPac HC
und Basic, Sub-Cell GT Systems (Biorad, München)
Gel documentation system Gel Doc™ XR+ System (Biorad, München)
CanoScan 9000F MARKII (Canon, Krefeld)
Ice machine Icematic F200 + D201 (Castel Mac SpA, Castelfranco Veneto,
Italy)
Incubation shaker Certomat®BS-1 (Sartorius Stedim, Goettingen)
Magnetic stirrer IKA®RCT basic RCT-B (IKA, Staufen)
Microplate reader Synergy HT Multi-Detection-Reader (BioTek, Bad
Friedrichshall)
Tecan GENios Pro (Tecan, Männedorf, Switzerland)
Microwave OMV330D-M (OK)
Microscope Leica DM IL (Leica, Wetzlar)
ProgRes® CF cool (Jenoptic, Jena)
Milli-Q® System Aquinta Ls with MemTap1, 0,2 µm PES (Membra-Pure,
Bodenheim)
Molecular interaction analysis
system
Biacore™ T200 (GE Healthcare, Freiburg)
pH-meter PB-11 (Sartorius, Göttingen)
Photometer Take3 Mikro-Volumen Platte (BioTek, Bad Friedrichshall)
BioPhotometer (Eppendorf)
Pipettes Manual  pipettes: Eppendorf Reference® 0.1-2,5µl, 0,5-10µl,
2-20 µL, 10-1000 µL, 100-1000 µL (Eppendorf, Hamburg),
DISCOVERY comfort-8/-12 20-200µl (Abimed , Langenfeld)
Motorized pipettes; Research®pro 5-100µl, Research®pro-8
50-1200µl (Eppendorf, Hamburg), Transferpette®-8 30-300µl
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PCR thermal cycler 2720 Thermal Cycler (Life Technologies GmbH, Darmstadt)
Peristaltic pump Masterflex L/S 7518-00 (Cole-Parmer, Novodirect GmbH
Kehl/Rhein)
Sequencer ABI Prism 3730 Capillar Sequencer (Applied Biosystems,
Foster City, USA)
Scales TE310S2 und TE64 (Sartorius, Göttingen)
Shaker VKS-75 control (Edmund Bühler, Tübingen)
Software Aida Image Analyzer 4.27.039 (Raytest, Straubenhardt)
Adobe Photoshop CS5.1 (Version 12.1 x64Adobe)
Adobe Illustrator CS5 (Version 15.1.0, Adobe)
BIAevaluation Software (GE, Freiburg)
Biacore T200 Evaluation Software V1 (GE, Freiburg)
CLC Main Work bench 6.9.1 (CLC bio, Aarhus,
Denmark)
Clone Manager Professional Suite Version 8 (Sci-Ed
Software, Cary NC, USA)
Chromas 1.45 (Technelysium, South Brisbane QLD,
Australia)
OriginPro 8.1SR1 (OriginLab, Additive GmbH,
Friedrichsdorf)
Microsoft office 2010 : Excel, Outlook, Powerpoint, Project,
Visio, Word (Microsoft)
Sonication system Sono Plus HD 2070 + probes (Bandelin, Berlin)
Sterile bench Biowizard (Kojair Tech Oy, Vilppula, Finnland)
Suspension mixer CMV (Fröbel Labortechnik GmbH, Lindau)
Timer Rotilabo®-Signal-Timer (Roth, Karlsruhe)
Thermomixer Thermomixer®comfort/compact (Eppendorf, Hamburg)
Vortexer Vortex-Genie 2 (Scientific Industies, New York, USA)
Water bath TW20 (Julabo, Seelbach)
II.2 Methods
II.2.1 Recombinant DNA methods
II.2.1.1 Cultivation of E. coli DH5 and storage
For cloning experiments, competent E. coli DH5 (II.2.1.2) was used. The cells were grown in
Luria-Bertani-(LB-) medium (II.1.5) or on agar LB-plates (LB-medium containing 1.5%
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(w/v) agar) with 100 µg/ml (v/v) ampicillin at 37°C (Sambrook and Russell 2001).
Transformed cells were cryo-conservated at -80°C in LB-medium containing 25% (v/v)
glycerol.
II.2.1.2 Generation of chemical competent bacteria
Chemically competent bacteria were generated by using the rubidium chloride method
(Hanahan 1983, Sambrook et al. 1989). Aliquots of 50 µl were stored at -80°C until use.
II.2.1.3 Isolation and extraction of DNA
For plasmid isolation from E. coli DH5α cells (II.2.1.1) and for DNA extraction from agarose
gels NucleoSpin® kits were used (Macherey-Nagel). The procedure was performed according
to manufacturer’s recommendation. The optional washing step with AW buffer was always
included.
II.2.1.4 Polymerase chain reaction (PCR) and splicing by overlap extension (SOE)-PCR
The PCR is a standard method for the amplification of DNA-fragments (Saiki et al. 1988).
Colony-PCR was used after transformation of bacteria for the verification of successful
cloning and transformation. One picked clone was transferred to a master plate (II.2.1.1) first
and was added to 19 µl ultrapure water from the Milli-Q® System provided in a PCR tube
second. Finally, 6 µl master mix were added giving the PCR mixture (Table 9). The PCR
incubation scheme for Taq DNA polymerase is summarized in Table 10.
A specific form of PCR is the splicing by overlap extension (SOE)-PCR (Horton et al.
1989). For SOE-PCRs 0.1 µl Phusion High-Fidelity DNA Polymerase (Thermo Scientific) in
1x Phusion HF Buffer according to the manufacturer’s recommendation was used in stead of
the Taq DNA polymerase. The initial denaturation step and the final elongation were both
reduced to 2 min. The elongation time was calculated with 2000 bps/min.
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Table 9: PCR master mix for one reaction using Taq DNA polymerase.
Component Volume
PCR buffer (10x) 2.5 µl
MgCl2 (50 mM) 1.5 µl
dNTPs (10 mM each) 0.5 µl
5’ primer (10 pmol/µl) 0.5 µl
3’ primer (10 pmol/µl) 0.5 µl
Taq DNA polymerase (Fraunhofer IME) 0.5 µl
Table 10: PCR incubation scheme.
Step Temperature Duration Repetition
Initial denaturation 95°C 5 min -
Denaturation 95°C 30 s
25xAnnealing X°C 30 s
Elongation 72°C Y s
Final elongation 72°C 5 min -
X: The annealing temperature was determined by Clone Manager software.
Y: The elongation time for Taq DNA polymerase was calculated with 1000 bps/min.
II.2.1.5 Hybridoma rescue
The hybridoma rescue was performed according to Puettmann (Puettmann 2010). In short,
RNA was isolated using NucleoSpin® RNA kit (Macherey-Nagel) according to the
manufacturer’s recommendation (February 2013 / Rev.15) and the cDNA was synthesized
using gene specific primer (Igκ5_ and VHIgG1(COH30)) for mAb CyDI-4 and oligo dT
primer from SuperScript® III First-Strand Synthesis System for RT-PCR (Life Technologies)
for all others. The kit was used according to the manufacturer’s recommendation, except for
the amount of enzymes used (70%) and the initial denaturing temperature (70°C). Using the
5’-primers (GenBank association FM993988-FM994083) and 3’-primers (GenBank
association FM993421-FM993429) sequences for hCC-specific variable light and heavy
chains were amplified and cloned blunt end into pUC19c (Roth).
II.2.1.6 Restriction and ligation
The cloning of plasmids by restriction and ligation (Weiss and Richardson 1967) is a well
established technology.
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Preparative restrictions of 0.5-3 µg DNA were carried out in 50 µl and 10 µl reactions
with approx. 5 units enzyme (NEB). The ligation of restricted plasmid and fragment was
performed by T4 DNA Ligase (NEB) in a 10 µl reaction with a three-fold surplus of insert at
least.
II.2.1.7 Heat shock transformation of bacteria
Competent bacteria (II.2.1.2) were thawed on ice (10 min) prior to addition of DNA (10 µl
ligation reaction (II.2.1.6) and 10-500 ng plasmid DNA (II.2.1.3) respectively). After an
incubation of 20 min on ice the 42°C-heat shock (1 min) was performed followed by addition
of 1 ml LB-medium. After regeneration (approx. 1 h, rotating, 37°C) cells were plated on
selection agar (usually 10 µl, 100µl and the remaining volume) and incubated over night at
37°C.
II.2.1.8 Gel electrophoretic analysis of DNA
Gel electrophoresis is a standard method for the separation of different-sized DNA-fragments
according to their separation behavior in a gel matrix by applying a voltage (Kostner et al.
1971).
Gel electrophoresis was run in agarose gels (0.8% or 1.2% (w/v) agarose in 1x TAE
buffer (II.1.5)) at 80 V-140 V for 20 min-50 min according to the size of fragments and gels.
II.2.1.9 Sequencing
The analysis of DNA sequences was determined according to Sanger (Sanger et al. 1977).
The sequencing was performed at Fraunhofer IME, Aachen (Dr. Jost Muth) using the
ABI Prism 3730 Capillar Sequencer (Applied Biosystems). For sequencing 150 ng/1000 bps
of plasmid DNA and 30 ng of PCR fragment was mixed with 20 pmol primer. The determined
sequences were analysed by CLC Main Work bench 6.9.1 and Clone Manager Professional
Suite Version 8 software (II.1.11) respectively.
II.2.2 Eukaryotic protein production and purification
The transfection was performed according to the manufacturer’s recommendation using small
modifications. DNA and Roti®-Fect (Carl Roth), both 2–3 µg and 2–3 µl respectively, were
directly added to 300 µl RPMI medium (Life Technologies) and were mixed by gentle
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inversion followed by incubated for 30 min at room temperature. The mixture was added
dropwise to ~70–80% adherent HEK293T cells in a six-well plate. After 3–4 h R10 culture
medium was added.
Selection pressure was applied 2–3 d later by adding 100 µg/ml ZeocinTM. The cells
were selected based on ZeocinTM resistance for 2 weeks. The cells were diluted ~1:10 twice a
week, and after 2 weeks protein expression and successful secretion into the culture
supernatant was analysed by SDS-PAGE (Laemmli 1970) and immunoblotting (Towbin et al.
1979). The cells were subsequently expanded to one triple flask (Nunclon™Δ) and
supernatant was harvested three times per week. The cells were removed prior to collection
(500 g, 25 min, 4°C). The pooled supernatant fractions were stored at 4°C until protein
purification.
The hCC and GFP-hCC were purified by immobilized metal ion affinity
chromatography (IMAC) (Porath et al. 1975). The cell supernatant was mixed with 10x
IMAC-BW buffer and passed simultaneously through glass and cellulose acetate filters
(0.45 µm, Sartorius Stedium) using compressed air. The protein was then loaded onto a Ni-
NTA Superflow Cartridge using a ÄKTA purifier and eluted using a gradient of IMAC
elution buffer. Batch processes were also carried out, this time using step elution. Eluted hCC
was dialysed against AEX buffer 1 for anion exchange chromatography (AEX). The hCC
fraction was purified with the AEX-matrix Q Ceramic HyperD F (Pall life science) by gravity
flow with hCC in the flow-through fraction. Contaminations were removed from AEX matrix
using AEX buffer 2.
The hCC-Hinge-Fc was purified by Protein A affinity chromatography after mixing the
supernatant with 4x Protein A binding buffer, filtering as above and passing through a column
containing Protein A Ceramic HyperD F on an ÄKTA purifier. The column was washed with
1x Protein A binding buffer prior to elution with Protein A elution buffer. The eluted protein
fraction was neutralized with Protein A neutralization buffer. The analytical purification of
antibodies was performed in batch mode (see II.1.5 for all buffer recipes).
II.2.3 Prokaryotic protein production and purification
E. coli BL21 (DE3) cells were transformed by heat shock (II.2.1.7) and a pre-culture was
cultivated (shaking, 37°C, overnight). The main culture (4x 400 ml in 2-l flasks) was
inoculated with the pre-culture at a ratio of 1:50 and incubated as above until the OD600
reached 0.8–1. At this point, protein expression was induced with 0.1 mM IPTG. The cells
were harvested after 4 h and pelleted at 4000 g for 10 min then stored at –80ºC. Glutathione
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S-transferase (GST) and stGST-hCC (stabilized GST-hCC) were purified as described in the
“Manual Purification Protocol” from the “Glutathione Affinity Handbook, May 2010”
(Quiagen).
II.2.4 Protein-analytical methods
After purification all protein solutions were analysed according to following methods.
II.2.4.1 Gel electrophoretic analysis of proteins
Discontinuous sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was
used to analyse protein solutions (Laemmli 1970). Proteins were separated according to their
size in a gel matrix.
Protein samples containing 5x protein loading buffer (II.1.5) were denatured for 5 min
at 100°C. According to the size of the protein 12%- or 15%-SDS-PAGE gels (Table 11) were
used for protein separation. Separation was performed at 160 V for 1 h in a Mini-PROTEAN
3 Electrophoresis System (II.1.11). SDS-PAGE gels were stained with “Coomassie staining
solution” for at least 20 min. The background color was removed by incubation of the gel in
“Coomassie destaining solution” (II.1.5).
Table 11: Composition of 12%- and 15%-SDS-PAGE-gels, respectively.
Component Separation gel Stacking gel
Tris-HCl, pH 8.8 (1 M) 375 mM -
Tris-HCl, pH 6.8 (1 M) - 125 mM
Acrylamid/Bisacrylamid (30:1) 12% or 15% (v/v) 5% (v/v)
SDS 0.1% (v/v) 0.1% (v/v)
TEMED 0.1% (v/v) 0.1% (v/v)
APS 0.1% (v/v) 0.1% (w/v)
II.2.4.2 Transfer and immunological detection of proteins
The immunoblotting of proteins comprises the transfer of proteins from a gel to a membrane
and their immunological detection (Towbin et al. 1979).
For immunoblotting, proteins were transferred from a SDS-PAGE gel (II.2.4.1) to a
nitrocellulose membrane (Roth) in the Mini-PROTEAN 3 Electrophoresis System (Biorad) using
TGS buffer (1 h, 330 mA). The membrane was blocked with 1% (w/v) BSA and incubated
subsequently with antibody solutions (all shaking, 1 h, at room temperature). In between all
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steps washing was performed with PBST. For membranes where GAMAP was used as
secondary antibody, bands were detected using NBT/BCIP in AP buffer as substrate. For
membranes where GAMHRP was used as secondary antibody, the substrate SIGMAFAST™
DAB was used (Sigma-Aldrich) which was applied according to the manufacturer’s
recommendations (All buffers and solutions: II.1.5).
II.2.4.3 Determination of the purity of protein preparations
The purity of protein preparations was determined using AIDA software (II.1.11). The
analysis was performed on Coomassie-stained SDS-PAGE gels. Therefore intensities in one
line were transferred into a graph.[%] = area determined for the band of interestarea determined for the whole lane ∗ 100
II.2.4.4 Dialysis and storage
Purified protein solutions (II.2.2, II.2.3) were pooled according to their purity and dialysed
against 1x PBS after analysis (II.2.4.1). Dialysed protein solution was aliquoted and stored at
–80°C until use.
II.2.4.5 Determination of protein concentration
The concentration of a protein solution was determined by Pierce® BCA Protein Assay Kit
(II.1.2) which, with one exception, was used according to the manufacturer’s
recommendation. The volumes for standard (BSA and IgG, 2 µg-0 µg) and analysed protein
solution were reduced to 10%.
II.2.5 Immunization of mice and determination of antibody titres
Mice were immunized essentially as previously described (Feller et al. 2013). Briefly, 60 µg
of stGST-hCC was injected subcutaneously as the prime immunizations, followed later by a
30 µg boost. Mice were boosted on three consecutive days without adjuvant prior to the
generation of hybridoma lines.
Titres were determined as previously described (Feller et al. 2013) with the protocol
adapted for antigen coating, the dilution range and the secondary antibody. Wells were coated
with 50 ng stGST-hCC/hCC or GST per well (1 µg/ml) dissolved in 50% (v/v) PBS and 50%
(v/v) 2x coating buffer (II.1.5). The murine sera were serially diluted in the range 1:800 to
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1:4 096 000. The ELISA steps are summarized in Table 12. Absorption was read at 405 nm
(Synergy HT Multi-Detection-Reader).
Table 12: Indirect ELISA protocol.
Step Concentration Volume Duration/Repetition
Coating 1 µg/ml antigen in 50% (v/v) PBS and 50%
(v/v) 2x coating buffer
50 µl 2 h, room temperature
or over night, 4°C
Blocking 1% (w/v) BSA in PBS 200 µl 1 h
1st Ab Serial diluted serum (1:800 to 1:4 096 000) 50 µl 1 h
2nd Ab 1-2 µg/ml GAMHRP in PBS (1.74 µg/ml) 50 µl 1 h
Detection ABTS 50 µl 45 min
II.2.6 Hybridoma generation and limiting dilution
B-cells were immortalized by creating hybridoma lines (Köhler and Milstein 1975) using
murine myeloma cell line SP2/0-AG14 (DSMZ) in a 1:1–1:2 ratio. The cells were fused by
exposing them to polyethylene glycol prior to selection in HAT medium (1x hypoxanthine-
aminopterin-thymidine, 0.5 µg/ml IL-6 (Pan-Biotech), 20% fetal calf serum (Biochrom), 1x
-mercaptoethanol in RPMI). Cells were selected for two weeks in 96-well plates. Positively
selected cells (II.2.7) were subjected to limiting dilution in HT-medium (1x hypoxanthine-
thymidine (Pan-Biotech) in RPMI). The diluted cell hybridoma cell cultures were analysed
depending on cell growth seven to nine days after limiting dilution (II.2.7). Monoclonal
hybridoma cell lines were identified by microscopy and were subsequently stepwise adapted
to R10 culture medium. Polyclonal cell lines were subjected to additional limiting dilutions.
II.2.7 Selection of monoclonal hybridoma cell lines
Monoclonal hybridoma cell lines were selected by indirect ELISA and sandwich ELISA
(sELISA). The indirect ELISA was performed using GST, stGST-hCC, hCC (produced with
Igκ targeting signal) and BSA as described for measurement of titres except that 30 μl
hybridoma supernatant were used in stead of diluted serum (II.2.5). For the sELISA goat
αhuman IgG (GAH, Thermo Scientific) was used to capture hCC-Hinge-Fc prior to
application of hybridoma supernatant. The ELISA results were correlated to the
microscopically determined cell number to exclude hybridoma cell lines producing low
affinity antibodies.
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II.2.8 Mouse immunoglobulin isotyping ELISA
Hybridoma supernatant was used for the determination of the isotype of hCC specific mAbs
using the “Mouse Immunoglobulin Isotyping ELISA Kit” (BD Biosciences) according to
manufacturer’s recommendation.
II.2.9 Cryopreservation of monoclonal hybridoma cell lines
Monoclonal hybridoma cell lines were cryopreserved for long-term storage (-150°C
to -160°C). Three T75 cell culture flasks bearing hybridoma cells in R10 medium were
harvested (200 g, 5 min), resuspended in freezing medium and split à 1.8 ml into 11 tubes.
Cells were frozen in a Mr. Frosty™ Freezing Container (Thermo Scientific) until -80°C and
subsequently transferred to a cryogenic tank with liquid nitrogen.
II.2.10 Production and purification of monoclonal antibodies
After selection of monoclonal cell lines by ELISA and sELISA (II.2.5, II.2.7) the cells were
adapted to serum-free medium (ISF-1, Merk Milipore), expanded and 8 x 106 cells were
transferred into a CELLine bioreactor (Sigma-Aldrich). The supernatant was harvested twice
a week, separated from the majority of cells by centrifugation (200 g, 5 min, room
temperature) and stored at 4°C ready for protein purification. The mAbs were purified on a
Protein G affinity column (KPL) according to manufacturer’s recommendation using the
ÄKTA purifier system and a step-elution. Prior to purification, the supernatant from different
harvest time points was pooled and passed through a 0.45-µm PVDF syringe filter to remove
all larger particles.
II.2.11 Surface plasmon resonance (SPR) spectroscopy
The analysis by SPR was performed by Holger Spiegel using the Biacore™ T200 (Biacore,
GE Healthcare, Uppsala, Sweden) on a RAM(Fc)-chip biochip which is a functionalized
CM5-S-Series-chip with mouse-specific antibodies immobilized by Mouse Antibody Capture
Kit (Biacore, GE Healthcare, Uppsala, Sweden). Either 1:6-diluted hybridoma supernatant
and 18 µg/ml hCC or purified antibody solution and 10 µg/ml hCC were used for analysis of
binding characteristics.
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II.2.12 Analysis of a preliminary newly-designed chip-based detection system
The chip behaviour was analysed in a two-well chip system (Figure 20). The measurement
was performed while 1V was set for the reference electrode. The change of the voltage (out)
between two assay wells was monitored while GST (1.6 mM) was added to the first well and
subsequently to the second well. The GST-volume of 10 µl and 50 µl, respectively, was added
to ~500 μl PBS.
II.2.13 Depletion of hCC from normal human serum
The hCC-depleted normal human serum (dNHuS) was produced for the dilution of reference
material in the replacement assay using an hCC-specific affinity matrix prepared from mAb
CyDI-1 and NHS (N-hydroxysuccinimide)-activated SepharoseTM 4 Fast Flow (GE
Healthcare). A “Vivaspin 15R” (30 molecular weight cut-off, Sartorius Stedim) column was
used to concentrate 6 mg of the antibody and exchange the buffer.
Antibodies were coupled to 0.5 ml NHS-activated Sepharose according to manufacturer’s
recommendations for 1 h at room temperature. After overnight inactivation the matrix was
washed with alternating NHS buffer C and NHS buffer D for six times. Prior to storage, one
elution step with sterile glycine buffer was carried out and a neutralization with sterile PBS.
For the depletion of hCC from 5 ml NHuS, two incubation steps were carried out using the
mAb CyDI-1 matrix. First using a batch approach (overhead mixing, 15 min, room
temperature), followed by a gravity flow purification at room temperature. An intermediate
elution step was carried out as described above (see II.1.5 for all buffer recipes). Successful
depletion was confirmed by sELISA (II.2.14).
II.2.14 Confirmation of hCC depletion by sELISA
The sELISA was based on mAb CyDI-1 as the capture antibody and a biotinylated mAb
CyDI-2 as the secondary antibody. For the biotinylation of mAb CyDI-2, a cold protein
solution (1.5 mg in biotinylation buffer A was incubated with 756 µl biotinylation buffer B
for 30 min at 4°C in the dark. The solution was dialysed against 1x PBS (4°C, overnight) and
biotinylation buffer C was added to the protein solution at a 1:9 (v/v) ratio followed by
overhead mixing for 2 h at room temperature. The solution was dialysed as above.
Polypropylene microwell plates (Ratiolab GmbH) were used for sELISA. All steps are
summarized in Table 13. In between steps, plates were washed three to five times with PBST.
If not stated otherwise, all incubation steps were performed at room temperature.
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Table 13: sELISA protocol.
Step Concentration Volume Incubation
temperature/time
Coating of 1st Ab 500 ng mAb CyDI-1 in in 50% (v/v) PBS
and 50% (v/v) 2x coating buffer
50 µl 4°C, over night
Blocking 5% (w/v) milk powder in PBS 300 µl 1 h
Ag dNHuS and non-dNHuS respectively 50 µl 1 h
2nd Ab Biotinylated mAb 161 in PBS (1:5000) 50 µl 1 h
StrepPO 0.2 μg/ml in PBS 50 µl 45 min
Detection ABTS 50 µl 45 min
StepPO =Peroxidase-conjugated Streptavidin (Jackson ImmunoResearch Labaratories, INC.)
II.2.15 Fluorescence-based replacement assays
Antigen replacement on mAb CyDI-4 was visualized using the fluorescent fusion protein
GFP-hCC in addition to hCC. The assays were carried out using black high-binding plates
(Greiner) in triplicates at room temperature. All steps involved 50 µl aliquots except the
blocking step, in which 300 µl of blocking buffer were applied. The coating solution
comprised the protein dissolved in 50% (v/v) PBS and 50% (v/v) 2x coating buffer. All other
solutions comprised the protein in PBS only. In between steps (Table 14) the plates were
washed three times with PBST. Only one antigen at a time was used and the order of
application was varied so both directions of replacement could be tested. A Tecan GENios
Pro System was used for readouts after filling the wells with PBS (10 s of orbital shaking at
100 rpm and 20 s settle time prior to measurement, 485 nm excitation, 520 nm emission,
circle pattern, 3x3 number of reads, gain 50, 37°C). The assay was also carried out using the
fluorescent protein as the second antigen (positive control) and the non-fluorescent protein as
the second antigen (negative control). PBS was used instead of the first antigen and for
incubation steps after the first readout. Background fluorescence was measured, using GFP-
hCC alone (blocking and first antigen step only, Table 14).
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Table 14: Fluorescence-based replacement assay protocol.
Step Component Concentration Volume Incubation
temperature/time
Coating antibody CyDI-4 15 nM 50 µl 4°C, over night
Blocking BSA 1% 300 µl 1 h
First antigen GFP-hCC/hCC or
reference serum
300.8 nM
for GFP-hCC/hCC
50 µl 1 h
Second antigen hCC or reference
serum/GFP-hCC
300.8 nM
for hCC/GFP-hCC
50 µl 1 h
Readout PBS 1x 50 µl -
II.2.15.1 Repetitive replacement assay
For the repetitive replacement assay, alternating antigen solutions were used for the
replacement followed by a readout after each step. The assay was stopped after the fourth
readout. The assay was carried out three times.
II.2.15.2 Time-dependent replacement assay
For the time-dependent replacement assay, PBS was added prior to the second antigen. In
intervals of 10 minutes PBS was exchanges for the second antigen solution in three wells. The
assay was stopped and the readout obtained after 1 h. The assay was carried out three times.
II.2.15.3 Replacement assays with reference material
Reference material ERM-DA471/IFCC (IRMM) was used for the replacement assays instead
of self-produced hCC in PBS. The reference material is human serum standard spiked with a
defined amount of hCC. The replacement assay with reference material was carried out in
both directions as described of displacement for the repetitive replacement assay until the first
measurement except that non-diluted reference material was used instead of hCC in PBS.
As a second replacement assay, the reference material was serially diluted (1:2) with
hCC-depleted NHuS and was used to replace GFP-hCC as described for the repetitive
replacement assay until the first measurement. The positive control used for normalization
was the fluorescence signal resulting from replacement with dNHuS only. Due to limitations
in the available reference material, both assays were performed in triplicate with one
repetition in one direction.
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III Results
The hCC and hCC-fusion proteins should be cloned and produced to enable the generation of
hCC-specific mAbs and the development of an hCC-specific bioassay. For the development
of an immuno-based hCC-specific bioassay, suitable for an implant, it was of importance to
generate and identify hCC-specific antibodies which show the specifically required
association and dissociation characteristics for hCC and hCC-fusion proteins (I.6).
The results are grouped in five major parts:
1. The hCC, hCC-fusion proteins and GST
2. The generation and screening for hCC-specific mAbs
3. Production and analysis of hCC-specific mAbs
4. Analysis of mAb CyDI-4 in fluorescence-based replacement assays
5. Rescue of coding sequence for variable heavy (VH) and variable light (VL) chains.
III.1 The hCC, hCC-fusion proteins and GST
III.1.1 Cloning
Recombinant DNA techniques were used to generate constructs coding for hCC, hCC-fusion
proteins and GST. First, the hCC amino acid sequence (GenBank accession CAA36497.1)
was randomly reverse-translated and the resulting DNA sequence was subsequently codon
optimized for E. coli and Homo sapiens (GCUA, Kazusa). The resulting synthetic gene was
synthesized by Eurofins MWG Operon (VIII.1). As fusion partners to hCC, GST, GFP,
SNAP, a mutant O6-alkylguanine-DNA alkyltransferase, and the hinge region with the
crystallisable fragment of a human antibody (Hinge-Fc) were used. The coding sequences for
hCC, the hCC-fusion proteins and GST were assembled by SOE-PCR, standard PCR and in
vivo amplification (II.2.1.4, Figure 4).
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Figure 4: Illustration of the generation of insert for cloning.
DNA inserts for cloning were generated by SOE-PCR (A), PCR (B) and in vivo amplification (C) (II.2.1.4).
Primers with overlapping sequences ( ) and restriction sites ( ), respectively, were used for PCR
amplification ( ). R1-R2: Attachment of restriction sites and subsequently overlapping sequences,
R3: Annealing via overlapping sequences and synthesis of second DNA strand, R4: Amplification of DNA
fragment from R3.
All combinations used for insert generation and cloning are summarized in Table 18,
Table 19 and Table 20 (VIII.2). The physical cloning of pMS-L-hCC_2 and pMS-nathCC_2
was carried out by Christian Renzl within his Bachelor thesis which I supervised. The cloning
of pMS-L-GFP-hCC-MH carried out by Kai Fuhrman (Fraunhofer IME, Aachen) and of
pGEX5x3_MBTF together with Magdalena Bialon. The expression cassettes for the
prokaryotic and eukaryotic proteins are shown in Figure 5 and Figure 6, respectively.
Figure 5: GST and stGST-hCC prokaryotic expression cassettes.
Illustrated are the prokaryotic expression cassettes for production (II.2.3) of GST (A) and stGST-hCC (B) in the
pGEX5x3-based vector (pGEX_MBTF, pGEXTF). Ptac: tac promoter, FXa: Factor Xa cleavage site, GST:
Sequence encoding glutathione-S-transferase, stGST-hCC: Sequence coding for the stabilized fusion of GST
and human cystatin C, NcoI, NotI, EcoNI: Restriction sites.
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All ligations were used for the transformation of E. coli DH5α cells as previously
described (II.2.1.7). Positive clones were identified by Colony-PCR (II.2.1.4), used for in vivo
amplification of plasmids (II.2.1.1) and were subjected to plasmid isolation (II.2.1.3). The
sequence was verified by sequencing (II.2.1.9) prior to their use for protein production.
Figure 6: HCC, hCC-Hinge-Fc, hCC-SNAP and GFP-hCC eukaryotic expression cassettes.
Illustrated are the eukaryotic expression cassettes for the production (II.2.2) of hCC (A), hCC-Hinge-Fc (B),
hCC-SNAP (C) and GFP-hCC (D) in the pMS-vector (pMS, Stoecker et al. 2003). T7: T7 promoter/priming
site, TS: Native secretion signal of hCC, TS2: Secretion signal from the V-J2-C region of the mouse Igκ, His-
tag: Sequence encoding six histidine residues, Myc-tag: Sequence encoding c-Myc, hCC: Codon-optimized
sequence encoding the human cystatin C, hCC-Hinge-Fc: Sequence encoding a fusion protein comprising hCC,
the hinge-region and fragment-crystallisable of an human antibody, hCC-SNAP: Sequence encoding a fusion
protein comprising hCC and mutant O6-alkylguanine-DNA alkyltransferase, GFP-hCC: Sequence encoding a
fusion protein comprising enhanced green fluorescent protein and hCC, NheI, NotI, SfiI: Restriction sites,
pMS: Plasmid Michael Stoecker (Stoecker et al. 2003).
III.1.2 Protein production, purification and analysis
All proteins except GST and stGST-hCC were produced in HEK293T cells. For this
approach, HEK293T cells were lipo-transfected and selected by Zeocin™ (II.2.2). The
purification of all eukaryotic produced proteins was performed by IMAC with one exception.
The fusion protein hCC-Hinge-Fc contains no His-tag and was purified by affinity
chromatography using a Protein A matrix. In contrast to the fusion proteins, hCC was further
purified by AEX to increase purity (II.2.2).
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After purification, all protein samples were analysed by Coomassie-stained SDS-PAGE
(II.2.4.1) and immunoblotting (II.2.4.2). For example, Figure 7 shows the analysis of an hCC
purification by IMAC using the ÄKTA purifier system with a gradient elution.
Figure 7: Gel electrophoresis and immunoblot analysis of IMAC purified.
Fractions of an hCC (native secretion signal) IMAC-purification (II.2.2) were analysed by SDS-PAGE (A) and
immunoblotting (B) (II.2.4.1, II.2.4.2). The purification was performed using the ÄKTA purifier system with a
gradient elution. For the detection in immunoblotting α-HIS (0.44 µg/ml), GAMHRP (Fc, 1.74 µg/ml) and
SIGMAFAST™ DAB were subsequently used for the immunoblotting. 15%-SDS-PAGE gel, M: 7 µl Prestained
Protein Marker, Broad Range 7-175 kDa (NEB), 8 µl sample, 1: Load 2: Flow through, 3+4: Wash fractions, 5-
12: Gradient elution fractions.
GST and stGST-hCC were produced in the prokaryotic production system. E. coli BL21
(DE3) cells were transformed by heat shock (II.2.1.7). Proteins were produced using an
optimized IPTG concentration and were purified by affinity chromatography using the
Glutathione HiCap matrix (II.2.3).
Elution fractions were pooled, according to their purity, dialysed and aliquots were
frozen for long term storage (II.2.4.4). The total protein concentrations were determined by
BCA (II.2.4.3). The purity of all protein preparations was analysed by Coomassie-stained
SDS-PAGE (Figure 8), resulting the highest purity for hCC and GST, whereas some impurity
is present in all other protein preparations. The major bands visible correspond to the
anticipated sizes of the target proteins. The share of target protein was determined using the
image analysis software AIDA. On the basis of purity the concentration of target protein in
solution was calculated (II.2.4.3). After purification, the amount of eukaryotic produced
proteins ranged from 2.5 mg/l to 1.6 mg/l (Table 15). Comparing the yield, hCC (native
secretion signal) achieved the highest level. The hCC (native secretion signal) was used for all
analytical steps except for the hybridoma screening procedure. There the hCC (Igκ secretion
signal was used.
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Figure 8: Gel electrophoresis and immunoblot analysis of produced proteins.
Purified hCCs (II.2.2), hCC-fusion proteins (II.2.2, II.2.3) and GST (II.2.3) were analysed by SDS-PAGE
(II.2.4.1). 8-16% “Ready Gel® Tris-HCl Precast Gel” (Biorad), M: 7 µl Prestained Protein Marker, Broad Range
7-175 kDa (NEB), 500 ng protein, 1: hCC (Igκ secretion signal), 2: hCC (native secretion signal), 3: stGST-
hCC, 4: GFP-hCC, 5: hCC-SNAP, 6: GST.
Table 15: Protein yields of eukaryotically produced proteins after purification.
Protein Yield (mg/l)
1 hCC (Igκ secretion signal) 1.7
2 hCC (native secretion signal) 2.5
3 GFP-hCC 1.6
4 hCC-SNAP 2.2
III.2 The generation and screening for hCC-specific mAbs
III.2.1 Immunization and determination of antibody titres
The hCC-specific antibodies were generated in BALB/c mice. Three mice were immunized
with stGST-hCC (60 µg/30 µg antigen regime with GerbuMM as adjuvant). The development
of hCC-specific antibodies was monitored by measuring the titres on days 25 and 31. Beside
stGST-hCC, hCC and GST were used for titre determination, whereby the highest dilution
step showing a twice as high absorption as the background was defined as titre. The first
determined titres ranged from 1:6 400 to 1:25 600 and the second ranged from 1:51 200 to
1:102 400 depending on the mouse analysed. Prior to hybridoma generation mice were
boosted on three successive days with the antigen only using 30 µg of stGST-hCC (II.2.5).
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III.2.2 Hybridoma generation and selection of monoclonal hybridoma cell lines
Hybridoma generation was performed as previously described (II.2.6). After hybridoma
generation, hybridoma supernatant was analysed for hCC-specific binders by indirect ELISA
and sELISA analysis (II.2.7). The sELISA using hCC-Hinge-Fc was selected for screening
procedure to present the hCC without direct contact to the plate surface thus enabling the
exclusion of non-binders and neotope binders. Positively screened polyclonal hybridoma cell
lines were subjected to limiting dilution to generate monoclonal hybridoma cell lines (Figure
9, A). After each limiting dilution the hybridoma supernatants were analysed by indirect
ELISA and sELISA (Figure 9, B-E). The ELISA results were correlated to the
microscopically-determined number of cells in the corresponding wells to select hCC-specific
binders with distinct ELISA profiles. Ultimately, 12 monoclonal hybridoma cell lines were
identified (II.2.6), producing antibodies which showed specificity for hCC (Figure 9, #1-12).
Antibody containing supernatant, derived from the 12 selected hybridoma cell lines, was
subjected to SPR spectroscopy to analyse hCC association and dissociation characteristics of
antibodies.
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Figure 9: Hybridoma selection by indirect ELISA and sELISA analysis.
Hybridoma clones (II.2.7), derived from three mice, were selected by analysis of initially ~1300 hybridoma
supernatants (30 μl) in indirect ELISA (50 ng stGST-hCC, hCC, GST, 1% (w/v) BSA) and sELISA (50 ng hCC-
hinge-Fc) respectively using GAMHRP (Fc, 1.74 µg/ml) and ABTS (II.2.7). After hybridoma generation (A),
positively selected clones were subjected to limiting dilution (B-E, limiting dilution 1-4) to generate monoclonal
hybridoma cell lines (#1-12). #1: CyDI-1, #2: CyDI-2, #3: CyDI-3, #4: CyDI-4, #5: CyDI-5, #6: CyDI-6, #7:
CyDI-7, #8: CyDI-8, #9: CyDI-9, #10: CyDI-10, #11: CyDI-11, #12: CyDI-12.
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III.2.3 Analysis of mAbs from selected hybridoma supernatants by SPR
spectroscopy
The 12 selected mAbs (III.2.2) were analysed according to their hCC association and
dissociation characteristics by SPR spectroscopy. Antibodies from pre-diluted hybridoma
supernatants were initially captured and exposed to hCC followed by a dissociation phase
with PBS only (II.2.11). The response resulting from antibody capture varied according to the
antibody amount in the supernatant and is shown in response units (RU). From 12 potentially-
different initial mAbs, 5 showed appropriate yet distinct association and dissociation
characteristics for hCC (Figure 10). The dissociation was strongest and non-linear for mAb
CyDI-3, followed by mAbs CyDI-2 and CyDI-4. Almost no dissociation was detectable for
mAb CyDI-12 and no for mAb CyDI-1 in the given period of time. For further analysis all
selected hybridoma cell lines were used for up scaled production of antibodies.
Figure 10: SPR spectroscopic analysis of selected monoclonal hybridoma supernatants using hCC.
Supernatants from 12 selected monoclonal hybridoma cell lines (III.2.2) were subjected to SPR spectroscopy to
analyse the mAbs for their hCC association and dissociation characteristics in the Biacore T200® system
(II.2.11). The mAb were bound by the RAM(Fc)-chip surface in a time-dependent manner from pre-diluted
hybridoma supernatants (1:6), thus their capture levels differed according to their content in supernatants.
Subsequently hCC (18 µg/ml) was applied for 180 s, followed by a dissociation phase. sCyDI-1 to sCyDI-12:
Supernatants of monoclonal hybridoma cell lines which contained hCC-specific mAbs displaying appropriate yet
distinct association and dissociation characteristics for hCC.
III.2.4 Isotype analysis of mAbs
The isotype of selected mAbs (III.2.3) was of interest for the subsequent purification, the
assay development and the amplification of variable antibody sequences from hybridoma
cells. Prior to purification the isotype for all mAbs in hybridoma supernatant was determined
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by the “Mouse immunoglobulin isotyping ELISA kit” (II.2.8). All antibodies were found to
be of IgG1 and Igκ isotype (Table 16). Nevertheless, cross-reactivity was observed hybridoma
supernatant containing mAb CyDI-2, mAb CyDI-3 and mAb CyDI-4, respectively but stayed
clearly below the positive controls.
Table 16: Isotype of mAbs.
Hybridoma supernatants from five monoclonal hybridoma cell lines selected by SPR spectroscopic analysis
(III.2.3) were used to determine the isotype of mAbs using the “Mouse immunoglobulin isotyping ELISA kit“
(BD Biosciences) according to the manufacturer’s recommendation.
mAb Isotype VH Isotype VL
CyDI-1 IgG1 Igκ
CyDI-2 IgG1 Igκ
CyDI-3 IgG1 Igκ
CyDI-4 IgG1 Igκ
CyDI-12 IgG1 Igκ
III.3 Production and analysis of mAbs
III.3.1 Antibody production and purification
Prior to the production of mAbs, selected monoclonal hybridoma cell lines were
cryopreserved (II.2.9). Antibodies were purified by Protein G affinity chromatography
(II.2.10). Protein fractions and the neutralized elution sample were analysed by
Coomassie-stained SDS-PAGE (II.2.4.1) and immunoblotting (II.2.4.2). The purification of
mAb CyDI-1 is shown as example (Figure 11). Purification was successful as determined by
the presence of pure antibody in the elution fraction (Figure 11, lane 4). The arrows indicate
the heavy chain and the light chain respectively, matching to the theoretical sizes of 50 kDa
and ~25 kDa.
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Figure 11: Gel electrophoresis and immunoblot analysis of a mAb CyDI-1-purification by affinity
chromatography.
Fractions of a mAb CyDI-1-purification by Protein G-affinity chromatography (II.2.10) were analysed by
SDS-PAGE (A) and immunoblotting (B) (II.2.4.1, II.2.4.2). For detection in immunoblotting GAMAP (H+L,
0.12 µg/ml) and NBT/BCIP were used. 12%-SDS-PAGE gel, M: 7 µl Prestained Protein Marker, Broad Range
7-175 kDa (NEB), 10 µl sample, 1: Load 2: Flow through, 3: Wash fraction, 4: Elution fraction after pH
adjustment, HC: Heavy chain, LC: Light chain of an antibody.
All other purified antibodies looked basically the same except for mAb CyDI-2 which
had a larger light chain, running at the size of exactly 25 kDa, beneath which an additional
minor band is visible (Figure 12).
Figure 12: Gel electrophoresis and immunoblot analysis of purified mAb CyDI-1, CyDI-4 and CyDI-2.
Purified and dialysed mAbCyDI-1, CyDI-4 and CyDI-2 were analysed by SDS-PAGE (A) and immunoblotting
(B) (II.2.4.1, II.2.4.2). For detection in immunoblotting GAMAP (H+L, 0.12 µg/ml) and NBT/BCIP were used.
12%-SDS-PAGE gel, M: 7 µl Prestained Protein Marker, Broad Range 7-175 kDa (NEB), 10 µl sample, 1: mAb
CyDI-1, 2: mAb CyDI-4, 3: mAb CyDI-2, HC: Heavy chain, LC: Light chain of an antibody.
Due to their accessibility, purified mAbs CyDI-1, CyDI-2 and CyDI-4 were
subsequently analysed by SPR spectroscopy for their hCC and hCC-fusion protein association
and dissociation characteristics.
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III.3.2 Analysis of purified hCC-specific mAbs by SPR spectroscopy
After verification of hCC binding by SPR analysis, using hybridoma supernatant, it was of
special interest whether the mAbs would display similar association and dissociation
characteristics not only for hCC but also for the hCC-fusion proteins GFP-hCC, hCC-SNAP
and stGST-hCC. These were suspected to be essential key characteristics for the development
of a functional hCC-detection assay based on the repetitive antigen replacement. In contrast to
pervious SPR spectroscopy, purified mAbs were used for this analysis. After capturing mAbs
CyDI-1, CyDI-2 and CyDI-4 respectively, hCC and hCC-fusion proteins (GFP-hCC, hCC-
SNAP and stGST-hCC) were used for association and dissociation analysis (Figure 13, Figure
14, Figure 15 for mAb CyDI-1, CyDI-2 and CyDI-4, respectively).
Figure 13: SPR spectroscopic analysis of mAb CyDI-1 based on its ability to bind and release hCC and
hCC-fusion proteins.
The mAb CyDI-1, purified from hybridoma supernatant (sCyDI-1, III.3.1), was analysed for its hCC and hCC-
fusion protein association and dissociation characteristics in the Biacore T200® system (II.2.11). For this
approach, mAb CyDI-1 was captured to a response of ~150 RU. Subsequently hCC, GFP-hCC, hCC-SNAP and
stGST-hCC (10 µg/ml), respectively, were applied for 180 s each followed by a dissociation phase with buffer
only. The resulting changes in response are indicated in different colours.
The SPR analysis on mAb CyDI-1 showed differences in binding of hCC and
hCC-fusion proteins (Figure 13). The mAb CyDI-1 strongly bound hCC but only moderately
bound hCC-fusion proteins. Within seconds a plateau (maximum possible response) was
reached for hCC whereas none resulted for the hCC-fusion proteins. Within the dissociation
phase the slope did not return to baseline for the tested antigens, meaning all antigens were
tightly bound.
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Figure 14: SPR spectroscopic analysis of mAb CyDI-2 based on its ability to bind and release hCC and
hCC-fusion proteins.
The mAb CyDI-2, purified from hybridoma supernatant (sCyDI-2, III.3.1), was analysed for its hCC and hCC-
fusion protein association and dissociation characteristics in the Biacore T200® system (II.2.11). For this
approach, mAb CyDI-2 was captured to a response of ~150 RU. Subsequently hCC, GFP-hCC, hCC-SNAP and
stGST-hCC (10 µg/ml), respectively, were applied for 180 s each followed by a dissociation phase with buffer
only. The resulting changes in response are indicated in different colours.
For mAb CyDI-2, the SPR analysis revealed similar binding of hCC and a slightly faster
of all hCC-fusion proteins than detected on mAb CyDI-1. The dissociation is moderate for all
tested proteins but stGST-hCC where almost no dissociation (Figure 14).
Figure 15: SPR spectroscopic analysis of mAb CyDI-4 based on its ability to bind and release hCC and
hCC-fusion proteins.
The mAb CyDI-4, purified from hybridoma supernatant (sCyDI-4, III.3.1), was analysed for its hCC and hCC-
fusion protein association and dissociation characteristics in the Biacore T200® system (II.2.11). For this
approach, mAb CyDI-4 was captured to a response of ~150 RU. Subsequently hCC, GFP-hCC, hCC-SNAP and
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stGST-hCC (10 µg/ml), respectively, were applied for 180 s each followed by a dissociation phase with buffer
only. The resulting changes in response are indicated in different colours.
The SPR analysis on mAb CyDI-4 showed moderate association and dissociation
characteristics for all antigens. Beyond, the curves for all antigens lay exactly on top of each
other except for GFP-hCC whose binding was slightly slower (Figure 15). However, none of
the antigens led to a signal plateau under the given conditions.
The mAb CyDI-4 showed the most homogeneous association and dissociation
characteristics towards most tested proteins (Figure 15). This indicated that mAb CyDI-4 is
the most suitable for the development of the replacement assay. It is not possible to
differentiate between two proteins using standard immunological assays unless one of the
proteins is labelled or additional antibodies are included. Therefore the combination of hCC
and the fluorescent protein GFP-hCC was chosen to analyse replacement on mAb CyDI-4.
Additionally, the kinetics for mAb CyDI-1 was determined as the antibody showed no
dissociation under the experimental conditions (Figure 16). The dissociation constant was
determined to 2.9 x 10-10 M.
Figure 16: SPR spectroscopic analysis of kinetics for mAb CyDI-1 using hCC.
The kinetics for mAbCyDI-1 using hCC was determined in the Biacore T200® system (II.2.11) using linearly-
diluted hCC (528 nM to 1 nM). The resulting response curves are indicated in different colours.
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III.3.3 Analysis of mAb CyDI-4 and Cyst-13 specificity for hCC and GFP-hCC by
SDS-PAGE and immunoblotting
Before using mAb CyDI-4 in the replacement assay, its specificity for hCC and GFP-hCC
was confirmed by SDS-PAGE (II.2.4.1) and immunoblotting (II.2.4.2) in comparison with the
commercially available and well characterized mAb Cyst-13 (Sladewska et al. 2011). Two
major bands corresponding to hCC and GFP-hCC can be seen in the Coomassie-stained SDS-
PAGE gel (Figure 17, A). The same bands were detected by mAb CyDI-4 (Figure 17, B) and
mAb Cyst-13 (Figure 17, C), respectively.
Figure 17: Gel electrophoresis and immunoblot analysis of mAb CyDI-4 and Cyst-13 specificity for hCC
and GFP-hCC.
The specificity of mAb CyDI-4 and Cyst-13 for hCC and GFP-hCC was analysed by SDS-PAGE (A) and
immunoblotting (B-C). B: Immunoblot detected with mAb CyDI-4 (0.14 µg/ml), GAMHRP (Fc, 1.74 µg/ml) and
SIGMAFAST™ DAB, C: Immunoblot detected with mAb Cyst-13 (0.68 µg/ml), GAMHRP (Fc, 1.74 µg/ml)
SIGMAFAST™ DAB. 15%-SDS-PAGE gel, M: 7 µl Prestained Protein Marker, Broad Range 7-175 kDa
(NEB), 500 ng protein, 1: hCC, 2: GFP-hCC.
III.3.4 Analysis of cross-reactivity of mAb CyDI-4 by sELISA and indirect
ELISA
The cross-reactivity of mAb CyDI-4 for non-hCC components in the hCC-fusion proteins and
BSA was analysed by sELISA and indirect ELISA as described for the selection of
hybridoma cell lines (II.2.7) except that mAb CyDI-4 (0.71 µg/ml, 50 µl) was applied instead
of hybridoma supernatant. Therefore GST, BSA and non-hCC-fusion proteins were used
beside the specific hCC-containing antigens. The fusion proteins GFP-EpCam and SNAP-
EGF were kindly provided by Lea Hain and Magdalena Bialon, respectively. The analysis
was carried out by Kai Fuhrmann. As example, mAb CyDI-4 showed no cross-reactivity
(Figure 18). Analysis for the other mAbs showed basically the same results.
III Results 48
Figure 18: Analysis of cross-reactivity of mAb CyDI-4 by sELISA and indirect ELISA
The cross-reactivity of mAb CyDI-4 for non-hCC components in the hCC-fusion proteins and BSA was analysed
by sELISA (first bar) and indirect ELISA (second to ninth bar) (II.2.7) except that mAb CyDI-4 was applied
instead of hybridoma supernatant. The assay was performed in triplicates. The error bars represent the standard
deviation. Volumes of 50 µl were used for all steps but the blocking, where 200 µl were used. Goat α-human IgG
(0.80 µg/ml), antigen (1 µg/ml) and BSA (1% (w/v)) were applied for the coating step with antigens provided in
50% (v/v) PBS and 50% (v/v) 2x coating buffer. For the sELISA hCC-Hinge-Fc was bound GAH IgG as antigen
after the blocking step. For detection mAb CyDI-4 (0.71 µg/ml), GAMHRP (Fc, 1.74 µg/ml) and ABTS were
used. GAH to GFP-hCC: Positive-binders, GST to BSA: Non-binders.
III.3.5 Analysis of thermo-stability of mAb CyDI-4 by indirect ELISA and
sELISA
After conformation of specificity and exclusion of cross reactivity, the thermo-stability of
mAb CyDI-4 was to be analysed. For a human implant the antibody has to be thermo-stable at
the human body temperature. To analyse its thermo-stability, mAb CyDI-4 was incubated for
52 days at –80°C, +4°C and +37°C respectively and was analysed by indirect ELISA and
sELISA (II.2.7). For analysis the antigen concentration was kept constant while the mAb
CyDI-4 was serially diluted. The analysis was carried out by Kai Fuhrmann. This revealed
that mAb CyDI-4 did not lose its antigen binding capability significantly when stored at
different temperatures (Figure 19, A-E).
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Figure 19: Thermo-stability analysis of mAb CyDI-4 by indirect ELISA and sELISA
The thermo-stability of mAb CyDI-4 was analysed after incubation at –80°C, +4°C and +37°C (52 days) by
indirect ELISA (A-D) and sELISA (E) (II.2.7) except that serially diluted mAb CyDI-4 was applied instead of
hybridoma supernatant (II.2.7). The assay was performed in triplicates. The error bars represent the standard
deviation. After incubation of mAb CyDI-4 at –80°C, +4°C and +37°C (52 days), volumes of 50 µl were used
for all steps but the blocking, there 200 µl were used. GAH (0.80 µg/ml), antigen (1 µg/ml) and BSA (1% (w/v))
were applied for the coating step with antigens provided in 50% (v/v) PBS and 50% (v/v) 2x coating buffer. For
sELISA hCC-Hinge-Fc was applied after the blocking step. For detection serially diluted mAb CyDI-4 (0.001-
11.3 µg/ml), GAMHRP (Fc, 1.74 µg/ml) and ABTS were used. The coated proteins were the following A: stGST-
hCC, B: hCC, C: hCC-SNAP, D: GFP-hCC, E: GAH (sELISA).
III.4 Analysis of a preliminary newly-designed chip-based detection system
The newly designed chip-based detection systems were analysed for their characteristics in
respect to drift behaviour, sensitivity and reproducibility, as well as the direction of signal
change which should depend on the protein charge. The detection principle was based on two
assay-wells between which the potential was determined and referred to a reference electrode
(Figure 20). For the chip-based measurement one solution at a time (protein solutions, amino
acid solutions and diluted PBS, respectively) was added subsequently to the first well and to
the second well (Figure 20, 1 and 2). Measurements were performed at the IMTEK by the all
projects partners (Fraunhofer IMS, IME and the IMTEK).
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Figure 20: Simplified illustration of the preliminary two-well chip-based detection system
Two assay wells (1 and 2) are placed on extended gates (3) which are connected by an electrolyte-bridge (4) to
the reference electrode (5). The extended gates, the reference electrode and a voltmeter (7) are in turn connected
to the chip-based readout circuit from the Fraunhofer IMS (6).
As an example, GST, as charged protein, was used to analyse the functionality of a
preliminary newly-designed voltametric two-well solution as chip-based detection system.
The analysis revealed a nearly continuous and almost linear signal increase (Figure 21)
whereas a stepped signal increase was expected upon addition of GST to the first well and a
stepped signal decrease, back to the signal starting level, was expected upon addition of GST
to the second well. Additionally, one would have expected a larger signal change for the five
times larger GST-volume used in the second approach (Figure 21, B). Beyond, signal
fluctuation was observed with an unclear cause (Figure 21, A, 401 s to 801 s).
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Figure 21: Analysis of a preliminary circuit for chip-based detection.
The measurements (II.2.12) were performed at the IMTEK with a preliminary two-well detection system. The
graphs are modified from Can Dincer (IMTEK). The voltage between two assay wells was monitored while GST
(1.6 mM) was added to the first well (1) and subsequently to the second well (2). The GST-volume of 10 µl (A)
and 50 µl (B), respectively, was added to ~500 μl PBS.
Those results made clear that the evaluation of the replacement assay on mAb CyDI-4
would not be possible in a chip-based detection system at any time soon. As consequence, a
plate-based system was established to enable the development and verification of the bioassay
in parallel to the development of the chip-based detection system.
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III.5 Analysis of mAb CyDI-4, hCC and GFP-hCC for their suitability in
fluorescence-based replacement assays
The fluorescence-based replacement assay was established to analyse the ability of hCC to
replace hCC-fusion protein on hCC-specific mAb CyDI-4 and vice versa (Figure 22).
For all following assays the background fluorescence was determined and subtracted
from the readings from all other wells before the signals were normalized against the positive
control. The normalized fluorescence intensity was displayed as a percentage relative to the
positive control, which was set at 100%.
Figure 22: Schematic overview of fluorescence-based replacement assays.
The schematic overview shows the controls and the assay of one fluorescence-based replacement. The assay
(II.2.15) was carried out in triplicate using black ELISA plates coated with mAb CyDI-4 and blocked with BSA.
As positive control fluorescent protein (GFP-hCC) and as negative control the non-fluorescent hCC was bound
to hCC-specific antibody. Additionally GFP-hCC was added to a blocked well to estimate background
fluorescence. For one replacement one antigen (e.g. GFP-hCC) was captured first and replaced with the second
(e.g. hCC) and vice versa before readout.
III.5.1 Analysis of GFP-hCC bleaching
For the evaluation of the fluorescence-based replacement assays it was of importance to know
the tendency of GFP-hCC for bleaching, which may be caused during assay handling or its
readout and may interfere with the replacement-based decrease in fluorescence. Therefore,
several GFP-hCC containing solutions with different concentrations were prepared and used
for the coating of black ELISA plates as previously described for the indirect ELISA (II.2.5)
and were analysed in the fluorescence reader (II.2.15). No reduction in fluorescence was
detectable over the time (Figure 23).
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Figure 23: Bleaching analysis of GFP-hCC.
The bleaching of GFP-hCC was analysed by five readouts, one more than used for the repetitive assays and four
more than used for all other replacement assays. Serially-diluted GFP-hCC (61.4-7.7 µg/ml), provided in 50%
(v/v) PBS and 50% (v/v) 2x coating buffer, was absorbed to a black plate (1 h at room temperature). After
washing 50 µl were applied and plate was read (II.2.15).
III.5.2 The repetitive replacement assay
The repetitive replacement assay was used to determine whether four successive cycles of
replacement could be achieved with readouts taken after each round. In the control wells hCC
and GFP-hCC were used as the second antigen, but PBS instead of the first (Figure 24). Each
assay was carried out three times in triplicate. The fluorescence in the positive control wells
declined in a non-linear manner between first and forth readout, and the fluorescence in the
negative control wells varied below the range of background.
The repetitive replacement assays with GFP-hCC and hCC (and vice versa) showed
stepwise changes in fluorescence intensity, with the direction of change depending on the
replacement protein (Figure 25). An overall reduction in fluorescence intensity between the
first two and last two fluorescence steps in each experiment was found, and was confirmed by
assay repetition. Furthermore, the replacement behaviour on the antibody over time was
investigated using a time-dependent replacement assay.
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Figure 24: Controls for the repetitive replacement assay.
For positive control in the repetitive replacement assay (II.2.15), GFP-hCC (50 μl of 300.8 nM) was incubated at
the same time as the second antigen in the first cycle of replacement and PBS only was used for the second to
fourth cycle. For negative control hCC was used. Readout was performed four times in total, one after each
replacement cycle. Each assay was carried out in triplicate (error bars represent standard deviations). The
background was subtracted from mean values and the resulting fluorescence was normalized to the positive
control from the first readout of replacement and was plotted as a percentage. The assay was carried out three
times (n = 1–3 indicated as black, white and grey bars). PC: Positive control with mAb CyDI-4/BSA/GFP-hCC,
NC: Negative control with mAb CyDI-4/BSA/hCC, * -****: First to fourth readout.
Figure 25: Analysis of the repetitive replacement characteristics on mAb CyDI-4 using GFP-hCC and
hCC.
The repetitive replacement assay (II.2.15) was performed on mAb CyDI-4 (50 μl of 15 nM used for coating)
with GFP-hCC and hCC (50 μl of 300.8 nM each). Four replacement cycles were carried out. As starting antigen
GFP-hCC and hCC were used, respectively. Indicated with an arrow () is the replacing antigen given second.
Each assay was carried out in triplicate (error bars represent standard deviations. The background was subtracted
from mean values and the resulting fluorescence was normalized to the positive control from the first readout of
replacement and was plotted as a percentage. The assay was carried out three times (n = 1–3 indicated as black,
white and grey bars).: Replaced with.
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III.5.3 The time-dependent replacement assay
The time-dependent replacement assay was used to determine the minimal time required for
one replacement and was carried out with GFP-hCC and hCC in both directions. In contrast to
the repetitive replacement assay, PBS was added to all assay wells prior to replacement. The
PBS was exchanged for the replacement reagent at 10-min intervals. The normalized
fluorescence intensities for GFP-hCC replaced by hCC are shown in Figure 26 and those for
the reverse replacement in Figure 27. When hCC was the replacement reagent, the signal
declined in a non-linear manner, and most of the change in signal intensity occurred after
30 min; after 50 min, the mean fluorescence intensity had fallen to 39% (Figure 26).
Figure 26: Analysis of the time-dependent replacement characteristics on mAb CyDI-4 replacing GFP-
hCC with hCC.
The time-dependent replacement of GFP-hCC with hCC (50 μl of 300.8 nM each) on mAb CyDI-4 (50 μl of
15 nM used for coating) was analysed (II.2.15). After the incubation of GFP-hCC, wells were filled with PBS. In
a 10-min interval PBS was exchanged for hCC containing solution. Each assay was carried out in triplicate (error
bars represent standard deviations). The background was subtracted from mean values and the resulting
fluorescence was normalized to the positive control from the first readout of replacement and was plotted as a
percentage. The assay was carried out three times (n = 1–3 indicated as black, white and grey bars).
When GFP-hCC was the replacement reagent, the signal increased also in a non-linear
manner, and most of the change in signal intensity occurred also after 30 min; after 50 min the
mean fluorescence intensity was 79% (Figure 27).
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Figure 27: Analysis of the time-dependent replacement characteristics on mAb CyDI-4 replacing hCC
with GFP-hCC.
The time-dependent replacement of hCC with GFP-hCC (50 μl of 300.8 nM each) on mAb CyDI-4 (50 μl of
15 nM used for coating) was analysed (II.2.15). After incubation of hCC, wells were filled with PBS. In a
10-min interval PBS was exchanged for GFP-hCC containing solution. Each assay was carried out in triplicate
(error bars represent standard deviations). The background was subtracted from mean values and the resulting
fluorescence was normalized to the positive control from the first readout of replacement and was plotted as a
percentage. The assay was carried out three times (n = 1–3 indicated as black, white and grey bars).
The dynamic range of the time-dependent replacement assay resulting from the repetition of
the time-dependent replacement assay at different time points is presented in Figure 28, which
shows the mean intensity values as percentages.
Figure 28: Dynamic range of time-dependent replacement.
The dynamic range in the time-dependent replacement assay on mAbCyDI-4 (50 μl of 15 nM used for coating) is
illustrated to both directions (II.2.15). After incubation with first antigen (50 μl of 300.8 nM), wells were filled
with PBS. In a 10 minutes interval PBS was exchanged for second antigen containing solution (50 μl of
300.8 nM). The mean intensity values of the replacement of GFP-hCC with hCC ( ) and the replacement of
hCC with GFP-hCC ( ), resulting from assay repetition of the time-dependent replacement assay and given in
percent, are shown at different time points.
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III.5.4 The replacement assay using reference material
All the assays described thus far were based on the use of recombinant hCC in PBS, but the
chip-based in vivo assay will need to work with hCC in human serum. Therefore the
replacement analysis was carried out using certified reference material (ERM-DA471/IFCC
(IRMM)) as the replacement reagent, comprising human serum spiked with a defined amount
of hCC.
A replacement assay was carried out in both directions to determine whether the assay
was directly compatible with undiluted human serum (Figure 29). The mean fluorescence
intensity, determined for replacement using reference material for both directions, was 33%
and 75%, respectively which confirms the replacement capabilities determined in the
replacement assays using PBS as carrier solution.
Figure 29: Replacement assay with reference material showing the assay in both directions.
The replacement of GFP-hCC with reference material (II.2.15) instead of self produced hCC and vice versa
analysed with the same incubation time used for the repetitive replacement assay. Each assay was carried out in
triplicate (error bars represent standard deviations). The background was subtracted from mean values and the
resulting fluorescence was normalized to the positive control from the first readout of replacement and was
plotted as a percentage. The assay was carried out three times (n = 1–2 indicated as black and white bars).
: Replaced with, Serum: Non-diluted reference material (ERM-DA471/IFCC (IRMM)).
The second assay with reference material was used to determine whether the range of
the assay covers the physiological and pathological concentrations of hCC in serum.
Therefore dNHuS was prepared and the success of depletion was confirmed using a sELISA
(II.2.13 and II.2.14). The dNHuS absorption signal was similar to the background, whereas
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that of the non-depleted serum was as high as the positive control (Figure 30). The detection
limit of the sELISA was 4 ng/ml hCC in PBS (data not shown) confirming that the hCC
content of dNHuS was ≤ 4 ng/ml.
Figure 30: Analysis of dNHuS by sELISA.
The depletion of hCC from NHuS (II.2.13) was analysed using sELISA (500 ng mAb CyDI-1and biotinylated
mAb CyDI-2 in PBS (1:5000), II.2.14). The assay (II.2.15) was carried out in triplicate (bars represent standard
deviations). The assay was performed with the following analysed samples: NHuS: normal human serum
(50 μl), dNHuS: hCC-depleted normal human serum (50 μl), PC: hCC (50 ng), NC: PBS (50 μl).
The reference material was serially diluted with dNHuS and used as a replacement
reagent for GFP-hCC to determine the range of the replacement assay. A concentration-
dependent reduction in fluorescence intensity (Figure 31) was observed, although an exact
relationship between hCC concentration and fluorescence intensity could not be determined.
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Figure 31: Replacement assay with serial diluted reference material showing the mean of assays.
Reference material was serially dilution with hCC depleted NHuS (5.3-0.2 µg/ml) and used to replace GFP-hCC
on mAb CyDI-4 in the replacement assay (II.2.15). Each assay was carried out in triplicate (error bars represent
standard deviations). The background was subtracted from mean values and the resulting fluorescence was
normalized to the positive control (signal resulted from replacement with dNHuS only) and was plotted as a
percentage. The assay was carried out three times (n = 1–2 indicated as black and white symbols).
III.6 Evaluation of assay in the revised chip-based system
Although the voltametric two-well solution was exchanged for an amperometric one-well
solution (Figure 32) and circuit was revised, the identified detection issues basically stayed
the same (e.g. drift effect and sensitivity, III.4).
Figure 32: Simplified illustration of the revised one-well chip-based detection system
One assay well (1) is placed on an extended gate (2) which is connected by a wire-bridge (4) to the reference
electrode (3). The extended gate, the reference electrode and a voltmeter (6) are in turn connected to the
chip-based readout circuit from the Fraunhofer IMS (5).
Consequently, no bioassay could be evaluated in the chip-based detection system until
the end of this study and therefore the identified best combination of mAb CyDI-4, hCC and
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stGST-hCC could not be analysed at all for its replacement characteristics and its suitability
for the detection principle in the sensor.
III.7 Rescue of coding sequences for hCC-specific VH and VL domains
The rescue of the coding sequences for VH and VL domains of the hCC-specific antibodies
was carried out for two reasons. First, hybridoma clones are not stable enough to produce
antibodies without any limitations (Strebe et al. 2010). Second, the genetic information for the
VH and VL domains is the key for antibody engineering. The genetic information for the VH
and VL domains of hCC-specific was identified and saved according to Puettmann
(Puettmann 2010).
Accordingly, the total RNA was isolated and used for cDNA synthesis with gene
specific primers and oligo(dT) primer respectively. After identification of suitable primer
combinations, sequences were amplified and inserted into pUC19c for in vivo amplification
(II.2.1.5). As example, Figure 33 shows the selection of suitable primer combinations for
mAb CyDI-2, where gene-specific synthesized cDNA was used as template. Whereas the
primer identification for mAb CyDI-2 was distinct, the result was more ambiguous for
oligo(dT) synthesized cDNA, showing more bands. No sequence could be amplified for mAb
CyDI-12 and the repeated amplification using new RNA and cDNA failed because the
hybridoma cell line stopped antibody production.
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Figure 33: Gel electrophoresis analysis of coding sequences for mAb CyDI-2 VH and VL domains.
The amplification (II.2.1.5) of the VH and VL domain sequences using different primer combinations was
analysed in a 1.2% (v/v) agarose gel by gel electrophoresis. I-IX: Negative controls (all primer combinations
with the appropriate lane numbering are to be found in Table 21), M: 2-Log DNA Ladder (0.1-10.0 kb).
1-32 VH: Analysed PCR reactions for the amplification of the VH domain sequence using different primer
combinations, 1-40 VL: Analysed PCR reactions for the amplification of the VL domain sequence (all primer
combinations with the appropriate lane numbering are to be found in Table 22). Positive PCR reactions are
indicated with black numbers.
For all other mAbs primer combinations were identified (Table 17) and VH and VL
domain DNA fragments were amplified. The sequences of amplification products were
determined by sequencing (II.2.1.9). Hybridoma rescue was performed in cooperation with
Kai Fuhrmann. All sequences were verified to be in frame junctions without inserted stop
codons (IMGT).
III Results 62
Table 17: Primer combinations used for amplification of hCC-specific VH and VL domains.
The GenBank accession numbers are given.
mAb domain 5' primer 3' primer
CyDI-1 VH FM994026-FM994030 FM993422
VL FM994031-FM994045 FM993429
CyDI-2 VH FM993998-FM994001 FM993422
VL FM994069-FM994072 FM993426
CyDI-3 VH FM993998-FM994001 FM993422
VL FM994069-FM994072 FM993426
CyDI-4 VH FM994006-FM994013 FM993423
VL FM994046-FM994049 FM993426
Additionally, the presence and position of complementarity determining region (CDRs) was
identified for all sequences according MacCallum et al. (Dr. Andrew C. R. Martin's Group,
MacCallum et al. 1996, VIII.4). The classification of FRs and CDRs determined for VH and
VL domains of CyDI-1 to -4 differ depending on the method used (Table 23). For the VH
domains only FR1 and FR4 are consistent in lengths independent from methods used. The
CDR1 and CDR2 lengths determined by IMGT are shorter by two and nine amino acids
respectively, while CDR3 is longer by two. The determined lengths for the VL domains
match only for CDR3. Lengths determined for CDR1 and CDR2 of VL domains are reduced
by five and four amino acids respectively. The identified germlines determined by IMGT
differ for mAbs derived from different origins (CyDI-1, CyDI-2/3, CyDI-4) but not for the
same (CyDI-2, CyDI-3, Table 24). The sequence comparison shows a high sequence
similarity between CyDI-2 and CyDI-3 and larger differences comparing CyDI-2/3 to CyDI-1
and CyDI-4 (Table 25). Beyond, a potential N-linked glycosylation site was identified for
CyDI-2 N26 (Kornfeld and Kornfeld 1985, (Table 25)).
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IV Discussion
An essential aspect of this study was the generation of antibodies with “non-mainstream”
characteristics. Whereas for most applications antibodies with fast association and slow
dissociations characteristics are needed, this is not applicable to this study. In contrast to
common antibodies, the much sought-after antibody should enable the replacement using hCC
and an hCC-fusion protein to both directions in a reasonable amount of time. Therefore the
antibody should have the following characteristics: a high affinity to ensure specificity but not
to high to release the antigen in a reasonable period of time, thereby enabling the day-to-day
determination of the hCC concentration in serum. As the association and the dissociation are
opposing characteristics there can only be a small margin where the sought-for characteristics
match. Beside the antibody, the antigens hCC and hCC-fusion proteins were required for
antibody generation, selection and analysis. The latter should bear a shifted isoelectric point
or enable modifications which bring in additional charges (Figure 2).
In short, hCC, hCC-fusion proteins and GST were produced and purified in sufficient
amounts and purities to enable the generation and selection of hCC-specific antibodies, as
well as their analysis. Using stGST-hCC for the immunization of BALB/c mice, an
hCC-specific response was successfully induced. Monoclonal hybridoma cell lines, producing
hCC-specific antibodies, were generated and established. From 12 initially selected
hybridoma cell lines, 5 were identified to produce antibodies with suitable yet distinct
association and dissociation characteristics for hCC. In SPR analysis, purified mAb CyDI-4
was identified to be best suited to be integrated into the chip system. In fluorescence-based
replacement assays mAb CyDI-4 enabled the repetitive replacement of hCC and GFP-hCC to
both directions. The compatibility of assay duration with clinical requirements was confirmed
by time-dependent replacement assay. Finally, the compatibility with undiluted serum and the
physiological as well as most of the pathological hCC concentration range in human serum
was successfully shown.
IV.1 HCC and its role in diagnostic
Mutations and polymorphism within the hCC genes are inducing amyloidogenic-based
pathology (Palsdottir et al. 1988, Olafsson and Grubb 2000, Janowski et al. 2001, Nilsson et
al. 2004). Although much effort has been invested to unravel the nature and role of non-
mutated hCC, in many areas it is still unclear whether hCC is directly involved in the
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prevention or promotion of diseases or not. The hCC is a cysteine protease inhibitor (Barrett
et al. 1984, Brzin et al. 1984), suggesting a regulatory role in health. Conversely, an
imbalance of the hCC content may lead to dysregulation and the cause of diseases. Beyond its
action as cysteine protease inhibitor hCC antagonises TGF-β in breast cancer, thereby
indicating a more diverse mode of action of hCC than one might have thought in the first
place (Sokol et al. 2005, Tian and Schiemann 2009).
The concentration of hCC was investigated in various cell types and body fluids in
physiology and pathology. The results reveal the concentration of hCC to be independently
correlating with many diseases (e.g. cancer, neurodegenerative-, kidney-, cardiovascular
diseases and so on, in summary I.1). Depending on the pathological state and type of disease,
the hCC concentration may be elevated or decreased suggesting hCC as a diagnostic marker
(Wilson et al. 2010, Wan et al. 2013). For example, hCC is highly expressed in human male
reproductive system but downregulated in prostate cancer (Jiborn et al. 2004, Wegiel et al.
2009). However, in multiple sclerosis and amyotrophic lateral sclerosis hCC is reduced in
CSF (Bollengier 1987, Wilson et al. 2010).
The investigation of connections and interactions between diseases and the
concentration of hCC is ongoing. Therefore, results have to be carefully interpreted. For
example in diabetes the hCC-serum levels are elevated. Thus, hCC in serum was suggested as
a potential marker but already the authors themselves explicitly hint to the issue that diabetes
and kidney disease at some point may be interconnected and both lead to an elevation of hCC
in serum (Sahakyan et al. 2011).
In kidney diseases, as well as in cardiovascular diseases the concentration of hCC is
elevated and correlated to progression of pathological state. However, the role of hCC as a
marker for the estimation of the GFR is discussed controversially, concerning its superiority
to the commonly used marker creatinine, but not its use in general. Many papers did not focus
on small exogenous molecules for the direct measurement of the GFR as reference for the
comparison of the hCC-based eGFR to the creatinine-based eGFR. This absence of such a
reference is critically reviewed and its use is pointed out to be essential for drawing validated
conclusions, especially as creatinine and hCC were not completely independent markers
(Delanaye et al. 2014, Levey et al. 2014). However, the direct measurement of the GFR by
exogenous marker is more time consuming as the estimation of the GFR based on the
concentration of endogenous markers, also explaining their widespread use as markers in
clinics (Voskoboev et al. 2012).
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In contrast to kidney diseases, the use of hCC-based eGFR and its value for diagnosis in
cardiovascular diseases is beneficial for risk classification and prediction of long-term
mortality even in patient with CKD (Urbonaviciene et al. 2011, Li et al. 2013, Nead et al.
2013). An increased hCC concentration in serum is associated to several subtypes of
cardiovascular diseases as arterial stiffness in elderly (Madero et al. 2009), inducible ischemia
among patients with stable coronary disease (Deo et al. 2009) and all-cause mortality among
women in general population (Toft et al. 2012). Furthermore, the sudden cardiac death risk in
elderly is independently associated to impaired kidney function, measured by hCC but not by
creatinine (Deo et al. 2010). Therefore instead of creatinine, hCC was suggested as marker for
the prediction of mortality and cardiovascular events in patients with chronic kidney disease
(Vigil et al. 2014). According to the WHO, ischaemic heart disease is the most prevalent
cause of death world wide (WHO 2013, Figure 34).
Figure 34: “Comparison of leading cases of death over the past decade, 2000 and 2011” (WHO 2013).
Compared are the world wide top 10 leading cases of death in 2000 and 2011. COPD: Chronic obstructive
pulmonary disease, lu: lung cancer.
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In conclusion, the observation of the hCC concentration in serum using an hCC-specific
diagnostic implant could help to estimate the risk state of patients in general and especially in
those with cardiovascular disease. This might enable a faster treatment of patients.
IV.2 Production of hCC, hCC-fusion proteins and GST
For the generation of hCC-specific antibodies, all subsequent analytical reagents and the
development of the replacement assay hCC, hCC-fusion proteins and GST were successfully
produced and purified from the eukaryotic (HEK239T cells) and prokaryotic (E. coli BL21
(DE3)) system. The gene encoding hCC was ordered as synthetic codon optimized sequence
instead of RNA isolation and cDNA synthesis for two reasons. First, codon optimization is
beneficial for the production of human proteins in E. coli (Burgess-Brown et al. 2008).
Second, the hCC gene is polymorphic and mutations on the amino acid level are connected to
amyloidogenic effects and pathology (Crawford et al. 2000, Paraoan et al. 2004, Szymanska
et al. 2012). For example, the native secretion signal directs the hCC precursor protein to the
secretory pathway where the precursor protein is processed and hCC is secreted (Paraoan et
al. 2001). In contrast, an A25T mutation within this leader directs the hCC precursor protein
to the Golgi apparatus where protein accumulates (Paraoan et al. 2004).
For the production of hCC in the eukaryotic expression system the efficiency of two
leader peptides was compared. The cloning of hCC (Igκ secretion signal) was facilitated by
SOE-PCR because cloning by restriction sites, led to non-secreted insoluble protein that only
could be detected after cell lysis under denaturing conditions (data not shown). In comparison
to the Igκ-leader, the natural leader leads to enhanced yields of ~47% after IMAC and AEX
purification. HEK293T cells, used as transgenic production platform in this study, are
generally not used for the eukaryotic production of hCC because the host hCC will interfere
with the introduced one. Therefore the prokaryotic production platform in E. coli is
established for untagged hCC (Abrahamson et al. 1988). However, this was no issue in this
study because no mutated or truncated, untagged hCC should be used. Additionally, the hCC
in this study was produced as recombinant protein bearing a carboxy-terminal His-tag because
the tag can be used to verify the complete synthesis of protein and its integrity after
purification. Beyond, the tag simplifies the purification of hCC from FCS-containing cell
medium. In literature, a two-step purification often is used for the concentration and
purification of hCC. To yield high-purity hCC, the protein was concentrated and purified by a
two-step strategy in this study as well.
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High-purity hCC, mainly needed for analytical steps, was also used for the immunization of
BALB/c mice. However, no hCC-specific immune response could be verified as will be
discussed in the next section. To solve this problem, GST as fusion partner was selected to
enhance the immune response. Beyond, GST is of acidic protein nature as was required for
the chip-based detection and additionally served as purification tag. The use of GST avoids
the co-purification of host proteins containing histidine, which unfortunately the purification
by IMAC is known for, and is beneficial for the purification of basic proteins in respect to the
obtained yields (Robichon et al. 2011, Polzikov et al. 2012). Initially, hCC was cloned into
the pGEX5x3-vector using the multiple cloning site (MCS). The production of GST-hCC
revealed the yield to be very low and the elution fraction to comprise three thin bands that in
size matched GST alone, full length GST-hCC and something in between both (data not
shown). The observed pattern of protein bands for GST-hCC might be the result of aberration
of protein synthesis or protein degradation during production and purification. Moreover,
GST-hCC was unstable at +4°C. The original vector contains a Factor Xa protease cleavage
site 5’ to the MCS. It was hypothesised whether the combination of remaining MCS and the
Factor Xa protease cleavage site might result in an unfortunate combination regarding the
protein stability. Removing both, the MCS and the Factor Xa protease, stabilized the fusion
protein stGST-hCC which comprised one band less after purification. The two remaining
bands corresponded in size to GST alone and the full length fusion protein (Figure 8).
Although this still was not the ideal, the yield and stability were enhanced enabling the
purification of sufficient stGST-hCC for immunization and subsequent analysis (Li et al.
2004).
In addition to GST, the fusion partners Hinge-Fc, SNAP and GFP were selected for
their characteristics. The human Hinge-Fc was selected to facilitate a more native presentation
of hCC in sELISA, than was possible in indirect ELISA. The presentation of hCC into the
reaction solution was enabled by capturing the hCC-Hinge-Fc fusion protein through its
Hinge-Fc part by the coated human-specific antibodies, thus avoiding possible changes within
the protein conformation. Thereby, the direct contact of hCC to the plate surface was avoided.
An additional advantage of the Hinge-Fc fusion was its ability to serve as a purification tag
for affinity chromatography by Protein A. The SNAP was selected because, beyond its
function as tag, it is an adapter for the coupling through O6-benzylguanine (BG). The
functions which are mediated thereby can be divers, like immobilisation, labelling with
fluorescent markers or, as intended in this study, enabling the labelling with charged
BG-modified particles for the modification of the charge content per molecule (Kolberg et al.
IV Discussion 68
2013, Puettmann et al. 2013, Stein et al. 2013). Finally, enhanced GFP was selected as fusion
partner because it enables the fluorescence-based discrimination between hCC and the fusion
protein for the replacement assay development in the plate-based format. Additionally, GFP is
an acidic protein, thereby fulfilling the requirement for the detection in the chip-based format.
In literature, GFP fusions with hCC are used to investigate its trafficking of through the cell
(Paraoan et al. 2001, Paraoan et al. 2004). In this way, the authors also showed hCC-GFP
fusions to be producible and stable in the eukaryotic system.
All eukaryotically produced fusion proteins were successfully concentrated by IMAC
though the purity of protein samples was slightly reduced in comparison to those of hCC due
to the use of IMAC only.
IV.3 Immunization, hybridoma generation and selection of hybridoma cell
lines
An hCC-specific mAb, showing the previously discussed characteristics (I.6), was required
for the development of the replacement assay. Although hCC-specific mAbs exist, the
characteristics they were selected for differ from the required ones. To address these issues,
mice were immunized to induce an hCC-specific immune response which enables the
establishment of monoclonal hybridoma cell lines.
The immunogenicity of hCC in mice was predicted using the “Immune Epitope
database and Analysis resource” tool to identify potential MHC-II T-cell epitopes (IEDB
Analysis Resource), that indicated moderate to low affinities. Although moderate affinities are
sufficient for the induction of a specific immune response (Feller et al. 2013), hCC purified
by IMAC and AEC did not induce an hCC-specific immune response in mice. The
commercially-available hCC-specific murine mAbs (Hytest) are generated using urinary hCC
from patients with renal impairment (Conti et al. 2006). Purified urinary hCC is a mixture of
three hCC variants, one full-length polypeptide with an isoelectric point (pI) of 9.2, and two
amino-terminal (N-terminal) truncations (by eight and nine amino acids, respectively) with pI
values of 7.8 (Popovic et al. 1990), which may explain its immunogenicity in mice. However,
the recombinant full-length hCC in this study was purified by AEX chromatography, thus
yielding a single polypeptide with the high pI. Ultimately, stGST-hCC was used to generate
hCC-specific antibodies in mice. GST is a traditional fusion partner increasing the solubility,
purity and immunogenicity of fusion protein in contrast to non-fused protein (Costa et al.
2014). In literature, titres and the definition of high titres is often missing but high titres are
needed for successful hybridoma generation (Wanczyk et al. 2013).
IV Discussion 69
In 1975, the hybridoma generation technology was invented by Köhler and Milstein
(Köhler and Milstein 1975). Since then, this method was used to generate a huge number of
hybridoma cell lines producing mAbs of various specificities which demonstrates the
importance and functionality of this method (Lu et al. 2007, Kim et al. 2012, Wanczyk et al.
2013). Therefore, this method was also used in this study. The combination of limiting
dilution for the generation of monoclonal hybridoma cell lines, indirect ELISA and sELISA
analysis works well but is both time and material consuming. An accelerated method is the
droplet-based microfluidic for the functional single-cell hybridoma screening. By this method
up to 300 000 hybridoma cells can be screened per day and high expression cells can be
selected from one hybridoma cell line, whose expression levels on single-cell basis are
varying to a high degree (El Debs et al. 2012). The use of sELISA analysis was found to be
necessary for screening procedure to exclude antibodies that bind hCC in ELISA experiments
but not when tested by SPR spectroscopy, as observed of other antibodies generated in house
(data not published). SPR spectroscopy is used extensively to analyse protein interactions
(Mack et al. 2011, Reddy et al. 2012, Yu et al. 2012, Peuscher et al. 2013). However, no
publication seems to show the characteristics of hCC-specific antibodies determined by SPR
spectroscopy. SPR spectroscopy helped to exclude low binders and potentially same
antibodies at an early time point and thereby significantly reduced the amount of effort for
further analysis. The possibility to select several identical hybridoma cell lines is a known
issue in the establishment of monoclonal hybridoma cell lines. Broering et al. showed three
unique sequences out of 19 potential hybridoma cell line candidates and four unique
sequences out of 51 immunized mice (Broering et al. 2009). Selecting 5 of 12
potentially-different hCC-specific mAbs showing suitable yet distinct hCC-binding
characteristics emphasizes the good yield of different antibodies obtained from three
immunized mice in this study. As the main emphasis in this study was placed on the
replacement assay, the dissociation property a mAb showed for the antigen was of special
interest. Antibodies were selected showing dissociation properties from very slow to very fast
as at this time point no data exists showing the characteristics an antibody should have to
enable a replacement of one antigen with the other.
The isotype of CyDI-1 to -4 was primarily determined to enable an efficient purification
by affinity chromatography. Nonetheless, the isotyping which revealed all antibodies to be
IgG1:κ isotype also indicating a successful class switch during immunization of mice.
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IV.4 Production, purification and analysis of a mAb
Prior to further characterization of hCC-specific mAbs they were produced on larger scale and
purified. For the production of mAbs, selected monoclonal hybridoma cell lines were cultured
in serum-free ISF-1 medium using CELLine bioreactors (Integra). Although the addition of
FCS to cell culture medium supports cell growth, its use is controversial discussed and
suggested to be avoided. The use of serum-free medium was presented to be beneficial in
several ways. First, variations that could be brought in by the use of different FCS batches can
be avoided thus standardizing the culture conditions. Second, the purification is simplified
because large contaminants, as immunoglobulins and albumin, are not present in serum-free
medium. Last, the replacement of FCS from medium is within ethics (Shah 1999, Aybay and
Imir 2000, Even et al. 2006). The mAbs were produced in CELLine bioreactors because they
simplify downstream processing and are superior to other cell culture flasks (Bruce et al.
2002). Within the CELLine flask, a permeable membrane keeps hybridoma cells and
antibodies concentrated while allowing the nutrient supply to come from a larger content of
medium. Thereby, the volume subjected to purification is reduced, minimizing the
purification time. Additionally, higher concentrated antibody solutions bind more efficiently
to affinity matrices thus increasing the purity. The isotype of antibodies, as previously
mentioned, is of great interest for their purification and was determined to be IgG1:κ for all
hCC-specific antibodies. As murine antibodies of IgG1 isotype are weakly bound by Protein
A, hCC-specific antibodies were purified by Protein G-affinity chromatography. The feature
of Protein G, showing high affinity for BSA and bovine immunoglobulin, was no issue for the
purification of hCC-specific antibodies due to serum-free cultivation of hybridoma cells (Page
and Thorpe 2002). The purified hCC-specific antibody solutions showed high purity. The
antibody content after purification ranged from ~11 mg to ~60 mg per purification from 34 ml
to 55 ml supernatant. The sizes of light chains are in accordance with the identified DNA
sequence. The VL chain of mAb CyDI-2 running higher in the SDS-PAGE-gel than the other
bears a N-linked glycosylation which most likely resulted the different running size.
However, a thin band slightly beneath the main band of VL chain of CyDI-2 might also result
from protein degradation during production and storage or from unfavourable purification
conditions. One disadvantage the Protein G purification shares with those of Protein A, is the
elution. In both applications acidification is used for elution of antibodies from matrices
which may reduce the functionality of antibodies (Koguma et al. 2013). Additionally, by the
neutralization procedure the volume of the elution fraction is enlarged. Recently, a thermo-
sensitive Protein A mutant was published, enabling the release of bound protein by the
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increase of temperature instead of acidification. Thereby, the development of “molecular
species” is reduced, which are visible in size exclusion chromatography for conventional
Protein A, and functionality of antibodies is tremendously increased. However, no
comparison to Protein G is enclosed (Koguma et al. 2013).
CyDI-1 showed no dissociation in SPR spectroscopy which suggests the mAb to be a
candidate for a common detection antibody. The determined dissociation constant is close to
the dissociation constants reported for high-affinity antibodies against H5N1 Influenza A virus
strains and supports the assumption that mAb CyDI-1 could be used as a common detection
antibody (Xiong et al. 2014). Beside the specificity for hCC, it was of greatest interest
whether one antibody would display similar association and dissociation chracteristics for
hCC and an hCC-fusion protein, as this property is essential for the replacement of one
antigen with the other. The hCC, stGST-hCC, hCC-SNAP and GFP-hCC were used as
antigens in SPR analysis. The SPR data identified mAb CyDI-4 as the most suitable for
replacement studies. Similar kinetics were assumed to be essential for a replacement as in
theory a higher affinity for any of the antigens was assumed to hinder or even prevent a
replacement. The only two hCC-fusion proteins having an acid fusion partner, as needed for
the chip-based detection principle, were stGST-hCC and GFP-hCC.
Prior to replacement analysis, the specificity of CyDI-4 for hCC was verified in
comparison of mAb Cyst-13 which is the only monoclonal antibody whose epitope was
determined and is linear (Sladewska et al. 2011). The linear epitope for mAb CyDI-4
identified by SDS-PAGE matches the observation of dissociation by SPR spectroscopy where
antibodies recognizing linear epitopes have a reduced affinity in comparison to those
recognizing conformational epitopes.
Cross-reactive antibodies, partially underlying human diseases, are a naturally occurring
phenomenon (Xiu et al. 2010, Trier et al. 2012). The cause of cross-reactivity is assumed to
be determined by sequence and is the issue of current studies (Baum et al. 2013). Potential
cross-reactivity was analysed for mAb CyDI-4, especially as the hCC-specific mAbs were
induced with a fusion protein, and could be excluded for protein parts others than hCC itself
by indirect ELISA and sELISA analysis.
An antibody which should be used in an implant for humans has to stay functional at
+37°C, the human body temperature but the stability of the mAbs might be altered after
purification. Beside hCC, fusion proteins were used for the analysis of functionality by
indirect ELISA and sELISA to balance variations in between plates as observed for several
serial dilutions, where the signal drops to a higher degree from one plate to another than,
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according to the slope development, one might have assumed. However, mAb CyDI-4 was
verified to be stable showing that the purification did not significantly alter the conformation
and thereby the stability.
Although, the mAb CyDI-4 was identified by SPR spectroscopy to have the highest
potential for enabling replacement of one antigen with the other and was shown to fulfil the
requirements for specificity, cross-reactivity and thermo-stability, only one antigen at a time
was analysed by SPR spectroscopy and the assumed potential had to be verified.
IV.5 Analysis of a preliminary newly-designed chip-based detection system
and evaluation of assay in the revised chip-based detection system
The chip-based evaluation of a bioassay was not possible until the end of this study. Even
though, the chip-based detection system was changed from a voltametric two-well solution to
an amperometric one-well solution and the circuit was revised several times, no significant
and reproducible chip-based measurements were possible. One major problem resulted from
drift effects which were observed independently from the usage of biological components and
seem to come from the detection system itself. Drift in electrical systems is a general problem
(Skjaervold et al. 2013). Even for established detection devices drift is observed, though to a
smaller degree and over a larger period of time (Solinst 2013). In our case, systematic drift
ranged to a degree where the qualified evaluation of protein and amino acid measurements
was impossible. Potential causes for this drift effects could have been diverse, like the
alteration of the reference electrode, which might have drifted itself, thereby altering the
reference value over time, or the alteration of the chip surface. Additionally, the direction of
signal change depending on the characteristics of protein posed a problem because it was not
possible to detect a stepwise signal change. Beyond, unforeseeable signal changes occurred
were the cause could not be clearly identified. It was hypothesized that this effect might be
caused by insufficiently shielded cables and insufficiently shielded chip-based detection,
respectively. Finally, it seemed that the sensitivity of the chip did not match the biological
requirements. Beside proteins, pure charged arginine was used for the evaluation of the
quality of chip-based measurements in concentration far above their physiological occurrence
in proteins, to generate signals that can be clearer distinguished from those resulting from
system drift.
Until the end of this study the assays could not be used in the predicted chip-based
detection system on the electrical biosensor and therefore the identified best combination of
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hCC and stGST-hCC could not be analysed for its replacement characteristics and its
suitability for the detection principle.
As it became obvious that the evaluation of the best suited assay combination of mAb
CyDI-4, stGST-hCC and hCC, identified by SPR spectroscopy, was not possible in the
predicted chip-based detection system in a foreseeable amount of time, a plate-based
alternative was developed to analyse the replacement ability on mAb CyDI-4. Although the
SPR spectroscopy indicated that hCC and stGST-hCC were best suited for replacement
studies, another combination was required for the plate-based analysis. No protein
modification (e.g. labelling) or additional antibodies should be used for the differentiation
between the hCC-fusion protein and hCC, because the former may alter the binding affinity
and the latter will not be part in the final chip-based application. Hence, the combination of
hCC and the fluorescent protein GFP-hCC was used to analyse replacement on mAb CyDI-4.
IV.6 Analysis of mAb CyDI-4, hCC and GFP-hCC for their suitability in
fluorescence-based replacement assays
The fluorescence-based replacement assay was developed to analyse the predicted potential of
mAb CyDI-4 to enable replacement of one antigen with the other in both directions. As
mentioned before, the fluorescence-based discrimination was chosen for two reasons. First,
one can avoid the use of labelled secondary antibodies which are not present in the final
bioassay. Second, no modification of antigens was necessary which could have altered the
binding kinetics.
In the beginning, the fluorescence stability was verified to exclude interference with the
decrease in fluorescence caused by replacement and found to be stable which is in accordance
with literature (Cinelli et al. 2000).
In the repetitive replacement assay the positive control reflects the moderate
dissociation characteristic identified by SPR spectroscopy where the GFP-hCC is most likely
dissociating by the time and is washed away during the washing steps. The repetitive
replacement assay, as indicated by name, showed the repetitive replacement which is the key
feature for a continuous non-disposable system. For the assay themselves the subtraction of
background fluorescence and the normalization enabled a inter-assay comparison. With two
exceptions, the standard deviation for triplicates was below 2.4% in 91.6% of the cases, and
was even below 1% in 50% of the cases. Comparing the overall normalized fluorescence
intensity across assays, a higher variation in the standard deviation was noted (6.5–11.3% in
50% of the cases and 1.4–4% in the others). This is in accordance to literature where intra-
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assay imprecision is mostly lower than the inter-assay imprecision. However, the determined
inter-assay imprecision was quite high (Kyhse-Andersen et al. 1994, Finney et al. 1997). One
reason could be the use of antigens in PBS only. Although stepwise changes in fluorescence
intensity were observed, the maximum fluorescence intensity differed when comparing the
readouts from the first and third or the second and fourth replacements, where an overall
reduction in fluorescence intensity was noted which suggested that replacement was
incomplete. This may reflect the different starting conditions in the second replacement step,
and would have continued in the subsequent replacements. The decline in fluorescence
intensity indicated a higher affinity for hCC. This was not unexpected because it was
predicted by SPR analysis with mAb CyDI-4 and different antigens, i.e. GFP-hCC bound to
the antibody with marginally lower affinity than hCC and stGST-hCC.
Having shown the replacement with incubation steps of 1h, it was of interest how much
time is actually needed for the replacement because the time needed had to be compatible
with an implant. The time-dependent replacement assay revealed most of the change in
fluorescence intensity to take place within the first 30 min, which is fast for this type of
mechanism. Antibodies with slower dissociation rates would need more time, making them
unsuitable for this approach. Faster dissociation as seen for mAb CyDI-3 in the SPR
spectroscopy experiments with hCC could not be monitored in the replacement assay because
the signal fell to near background after replacement (data not show). It is likely that the rapid
dissociation caused the loss of signal during the washing steps. Additionally, one has to pose
the question whether an accelerated assay would be of interest. Normally the hCC
concentration in serum varies during the day (Larsson et al. 2008). Therefore it is not
necessary to have a quicker assay that enables complete hCC surveillance over an entire day,
indicating that our assay fulfils the time-based requirements. Regarding the dynamics
observed for time-dependent replacement, the increase in fluorescence observed with
GFP-hCC was more limited that the reduction in fluorescence observed with hCC. This
supports the hypothesis, as suggested for the repetitive replacement assay, that a slightly
higher affinity towards hCC might cause such a difference.
The use of reference material was necessary to determine the impact of other proteins in
the serum on the sensitivity of the assay for hCC, as most hCC ELISAs use diluted serum
samples (Lei et al. 2011, Waters et al. 2011, Chahed Bel-Ochi et al. 2013). However, the
replacement assay with reference material produced similar results to the assay in that hCC
was applied as a pure substance dissolved in PBS, and the standard deviations for triplicates
were smaller (all below 0.8%). As for the other replacement assays, the standard deviations
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for assay repetitions were higher than those observed for triplicates (1.3% and 4.3%,
respectively) but lower than observed for replacement assays using hCC in PBS. This reflects
the ability of proteins in serum to block the assay which works for this assay. Beyond that,
comparison of quantification assays using reference material unrevealed differences in the
determined hCC concentration by PETIA and PENIA respectively showing the importance of
standardisation. There, a 27.5%-increased hCC concentration was determined by PETIA
(Voskoboev et al. 2012).
Finally, the assay range was investigated, paying special attention to the typical
physiologically and pathologically relevant quantities for the concentration of hCC in serum.
The physiological range of serum-hCC concentrations including both genders covers
0.51-0.98 mg/l (Finney et al. 2000), whereas the pathological serum hCC concentrations in
elderly can increase to 6.11 mg/l in chronic kidney disease (Wei et al. 2014). The assay range
covered the physiological range of hCC concentrations in serum, and also most of the
pathological range. Thus, the sensitivity of assay even meets the requirements to detect the
serum concentration of hCC even in healthy patients although the implant was meant to
observe the development of pathology which is accompanied by an elevation of hCC in
serum. The hCC-specific replacement assay is the first its kind and therefore could not be
compared to others. With the exception of one value, where the standard deviation was
unusually high, the standard deviation for assay repetition was below 2.4% thus confirming
excellent reproducibility. The exception might result from an unequal quality of the used
ELISA plates and was observed several times within the experiments. Strongly reduced
fluorescence was sometimes observed for control wells which were coated with GFP-hCC
only, as well as within single and one time even within most wells of a plate (data not shown).
Nevertheless, the determined intra- and inter-assay imprecision was in between those
published for PETIA (0.9% and 2.2%) and PENIA (3.3% and 4.5%), both clinically used
methods (Kyhse-Andersen et al. 1994, Finney et al. 1997). However, the assay could only be
carried out twice so it was not possible to determine the statistical significance of these data.
Although a dose response relationship was observed, it was not possible to calculate a precise
relationship between hCC concentration and the fluorescence signal.
Using the fluorescence-based replacement assays, evaluation of the developed bioassay
was achieved in parallel to the evolution of the chip-based detection system.
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IV.7 Rescue of coding sequence for hCC-specific VH and VL VH domains
There are several reasons for the amplification of VH and VL domains from murine
hybridoma. Some hybridoma cell lines may show low production yield and others can stop
production upon prolonged cultivation (Strebe et al. 2010). However, the most frequent
reason to for the amplification of VH and VL domains is probably to enable antibody
engineering (Huston 2013, Flemming 2014, Turki et al. 2014).
Many publications deal with the specific amplification of sequences from hybridoma
clones coding for antibody VH and VL domains. The correctness of sequence, the amount of
primers involved and thereby the effort necessary are criteria that are considered while
choosing primer sets. In the case of direct engineering it additionally is of interest how simple
the subsequent cloning strategy is kept. Orlandi et al. used primer sets for the successful
amplification of variable sequences and their cloning into an expression vector. However, the
end sequences are determined by the primers used and may alter the function of antibody
(Orlandi et al. 1989). The idea of using primers, specific for the leader sequence, is rejected
due to higher variability in comparison to framework regions one (FR1) and the additional
sequence is disturbing in subsequent production or must be removed by additional cloning
steps. Using few degenerated primers, designed for the universal amplification from FR1 on,
works but also bears the danger of protein sequence mutations. In contrast to the leader
sequence, the constant region shows less variation and is used for amplification (Wang et al.
2000, Tiller et al. 2009).
The method, used for the amplification of variable hCC-specific sequences in this study
does for sure not reduce the effort for amplification. The primer set consist of 106 primers in
total. To identify the right primer combinations around 80 PCR reactions, including controls
and the use of 5’-primer mixes, have to be tested for one antibody prior to amplification of the
VH and VL sequence respectively. However, the use of non-degenerated primers, based on
the analysis of the NBCI Ig-blast database, might reduce the potential of end mutations and
maintain the functionality of variable chains. Furthermore, the use of primer mixtures instead
of degenerated primers, ensure the same primers stoichiometry in between primer batch. The
publication accompanying this method is in preparation Puettmann (Puettmann 2010).
The differences in between sequences derived from different origins are primarily
determined by the germline. For CyDI-2 and CyDI-3 the germlines are the same as they are
derived from one mouse. However, one can find eight substitutions between the VH chains
and five between the VL chains 5’ to the predicted junction sequence. Thus, the substitutions
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might result from somatic hypermutation, a mechanism contributing to the evolution of
antibodies affinity.
N-linked glycosylation (N-X-S/T but not N-P-S/T) is common in antibodies and affects
the biological function (Hamm et al. 2013). Although glycosylation often is found within the
constant domains, like the CH2 of IgGs, the glycosylation within the variable reagions also
occurres. N-linked glycosylation in the constant domains affect the effector function whereas
the glycosylation within the variable domain affects the binding (Radaev and Sun 2001,
Wright and Morrison 1993).
The classification of FRs and CDRs differ depending on the scheme and method used.
All schemes depent on the data sets used for the development of schemes. While the Kabat
scheme used sequencial data only the Chothia included structural data as well (Wu and Kabat
1970, Chothia et al. 1989, Abhinandan and Martin 2008). Unusual seqences may not fit into
the scheme. A standardization was invented with the FR-IMGT and CDR-IMGT numbering
(Lefranc et al. 2003). Therefore, the the FRs and CDRs determined for the VH and VL chains
of CyDI-1 to -4 differed depending on the method used. Nonetheless, both methods used lead
to the identification of FRs and CDRs within the given parameters for all analysed sequenses.
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V Outlook
Beside this study, which dealt with the development of an hCC-specific bioassay for a
diagnostic implantable biochip, chips emerged and are advancing in the field of diagnostics.
Sensors or chips are developed for various applications using a variety of detection principles.
One subsector of those chips comprises the biochips.
Biochips are continuously developed showing the deep interest in combination of
biological components and the chip-based detection. Thus, the biochip market is forecasted by
different sources to globally grow with a compound annual growth rate of 18.6% to 20.9% in
the next years and reach a value of US$11.4 billion by 2018 (Market-research report biochips
(2013), Ichiishi 2013). The subgroup “diagnostic biochips” is recently gaining more and more
attention. The emerged diagnostic biochips or sensor are based on a variety of detection
systems (Bunger et al. 2013, Feyzkhanova et al. 2014, Wang et al. 2014, I.4). As the
preliminary newly–designed and the revised chip-based detection system did not enable
specific and reproducible detection of charged proteins until the end of this study, the question
has to be posed whether the predicted chip-based detection system is capable to fulfil the
detection demands. Although an optical chip-based detection system was excluded as
potential detection principle for the hCC-bioassay due to considerations like energy supply,
miniaturization and integration at the beginning of the DiaImplant project, it has to be
considered as one possibility now. The technology within this field developed showing the
feasibility of optical biochips (Marcello et al. 2013).
Beyond the detection principle, the integration of the individual components was shown
to work for in vitro biochips (Zuo et al. 2013, Horak et al. 2014). An implantable biochip was
published in 2011 (Guiseppi-Elie 2011). Even though the integration for implantable biochips
is more challenging than for the in vitro biochips, regarding biocompatibility, energy supply
and stability, the successful development can not be excluded for the next years. Additionally,
the integration of immunoassays is feasible (I.4). Non-orientated antibody immobilization
methods can significantly reduce the activity of the antibody and the generally used
EDC/NHS approach only yields a low number of formed NHS-esters even through high
concentrations of chemicals are used (Soler et al. 2014). It is known that the orientated
immobilization of antibodies significantly enhances their functionality, thus enhancing the
sensitivity of assay (Voelker and Viswanathan 2013). Recently, a method was presented for
the orientated chemical-immobilization of full length antibodies to a gold surface which
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enables the by cysteamine and N-ethyl-N′-(3-dimethylaminopropyl) carbodiimide
hydrochloride/NHS (Ferreira 2014). Another approach, also enabling the orientated
immobilization of full length antibodies, is based on the commercially available ProLinkerTM
which is a molecule that binds the antibody by its Fc-part (Soler et al. 2014).
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VI Summary
The interest in diagnostic biochips is growing. However, most biochips are designed for ex
vivo applications. Beyond, an elevated serum human cystatin C (hCC) concentration
correlates with various diseases. Thus, hCC was suggested as biomarker. To meet the
requirements of an implantable biochip system it is essential to develop an hCC-specific
bioassay enabling repetitive measurements.
Within this PhD thesis an hCC-specific bioassay was developed which is based on the
concentration-dependant replacement between hCC and an hCC-fusion protein on an
hCC-specific antibody layer thus enabling the repetitive determination of the hCC
concentration. Therefore hCC, hCC-fusion proteins and GST were successfully cloned,
produced and purified. The fusion protein stGST-hCC was further used for the immunization
of mice. Thereby an hCC-specific immune response could be induced. With the use of the
hybridoma generation technology monoclonal hybridoma cell lines were established, which
enabled the selection and production of hCC-specific mAbs. The selection of monoclonal
hybridoma cell lines which produced hCC-specific antibodies was successful due to analysis
by indirect ELISA, sELISA and SPR spectroscopy. Selected hybridoma cell lines were used
for small scale production of hCC-specific mAbs which without purification were analysed
for their hCC association and dissociation characteristics by SPR spectroscopy. From 12
initially potential antibodies, 5 were identified to display specific yet distinct association and
dissociation characteristics towards hCC. For the replacement assay the dissociation
characteristics were of special interest, thus they were used to rank the antibodies. Whereas
mAb CyDI-1 showed no and CyDI-12 showed barely any dissociation, it was clearly seen for
mAb CyDI-2, CyDI-4 and to the highest degree for mAb CyDI-3. The five corresponding
hybridoma cell lines were used for the large scale production of mAbs, all producing mAbs of
the IgG1:κ isotype. All mAbs were purified by Protein G-affinity chromatography, yielding
pure protein. Due to their accessibility mAb CyDI-1, CyDI-2 and CyDI-4 were further
analysed by SPR spectroscopy. This time hCC-fusion proteins were used beside hCC for the
identification of suitable hCC and hCC-fusion protein combinations for the replacement
assay. The mAb CyDI-4 was identified as the antibody with the highest potential for enabling
replacement. Except for GFP-hCC, all fusion proteins and hCC showed exactly identical
association and dissociation behaviour towards hCC. The combination of hCC and stGST-
hCC was identified to be best by SPR spectroscopy, especially in respect to the end
application. However, the evaluation of the hCC-specific bioassay in the predicted chip-based
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detection system was not possible until the end of this study. In parallel to the chip evolution,
a fluorescence-based replacement assay was established for the evaluation of the replacement
ability on mAb CyDI-4. Thus, the discrimination between hCC and the hCC-fusion protein
was possible without the modification of antigens and the use of secondary antibodies,
respectively, which was essential as the former may alter the affinity and the latter is not
involved in the final bioassay. Using the mAb CyDI-4 and the antigen combination composed
of hCC and GFP-hCC a fluorescence-based replacement assay was developed, which meets
the implant requirements regarding the assay duration, the compatibility with human serum
and the required sensitivity for physiological and most of the pathological conditions.
Additionally, the assay standard deviation decreased upon use of reference material (hCC
spiced human serum) while maintaining the sensitivity. However, the repetitive replacement
assays revealed the replacement to slightly favour one replacement direction, as was predicted
by SPR analysis for hCC and GFP-hCC. Although the combination of GFP-hCC and hCC
was not ideal, and was only used to fulfil the detection requirements in plate-based format, the
results indicate that mAb CyDI-4 is an excellent antibody for the hCC-specific replacement
assay.
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VIII Appendix
VIII.1 Coding sequence for hCC and the N-terminal natural leader
Figure 35: Synthetic gene coding for hCC with natural targeting sequence.
VIII.2 Cloning
The primer combinations and templates, plus the target plasmids and restriction enzymes used
for SOE-PCR and cloning of Igκ-hCC and stGST-hCC are summarized in Table 18. The
primer combinations and templates, plus the target plasmids and restriction enzymes used for
PCR and cloning of hCC (with the natural targeting sequence) and GFP-hCC are summarized
in Table 19. Last the Plasmids and enzyme combinations used for in vivo amplification and
cloning of hCC-GFP, hCC-SNAP, hCC-Hinge-Fc, GST are summarized in Table 20.
Table 18: SOE-PCR for cloning.
Primer combinations and templates used for the three-step SOE-PCR, plus the target plasmids and restriction
enzymes.
Plasmid
(Protein)
PCR
step
5’Primer 3’ Primer Template Restriction enzymes
and target plasmid
pMS-L-hCC_2 R1 5’ IgK 3’ IgK pMS-LH22-IV NheI/NotI;
pMS-L-hCC-IVR2 5’ IgK-hCC 3’-HCC pCR2.1-hCystatin
R4 5’ IgK 3’-HCC R3
pGEXTF-Ago1
(stGST-hCC)
R1 5’ GST 3’ GST pGEX5x3-E2(1b) EcoNI/NotI;
pGEX5x3-E2(1b)R2 5’-hCC (GST) 3’-HCC pCR2.1-hCystatin
R4 5’ GST 3’-HCC R3
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Table 19: Insert generation by PCR.
Primer combinations and templates used for standard PCR cloning, plus the target plasmids and restriction
enzymes.
Table 20: In vivo amplification and cloning.
Plasmids and enzyme combinations used for in vivo amplification cloning.
Plasmid
(Protein)
Insert Restriction enzymes and target
plasmid
pMS-nathCC-SNAP-MH
(hCC-SNAP)
pMS-nathCC_2 NheI/NotI;
pMS-scFv2715-SNAP
pMS-L-hCC-Hinge-Fc
(hCC-Hinge-Fc)
pMS-L-hCC_2 NheI/NotI;
pMS-EGFRex-Hinge-Fc
pGEX5x3_MBTF
(GST)
- NcoI/NotI;
pGEX5x3-E2(1b)
Plasmid
(Protein)
5’-Primer 3’-Primer Template Restriction enzymes and
target plasmid
pMS-nathCC_2
(hCC)
5’ NheI
natlnt
3’-HCC pCR2.1-hCystatin NheI/NotI;
pMS-L-hCC-IV
pMS-L-GFP-hCC-MH
(GFP-hCC)
5`Sfi-hCC 3`-HCC pCR2.1-hCystatin SfiI/NotI;
pMS-L-GFP-scFvEpCAM
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VIII.3 Maps of pGEX- and pMS-based plasmids
VIII.3.1 Plasmids for prokaryotic protein production
Figure 36: Maps of pGEX-based plasmids
Ptac: tac promoter for inducible expression, Rlac: lac repressor protein binding site, GST: Sequence encoding
glutathione-S-transferase, FXa: encodes the factor Xa recognition site, stGST-hCC: Sequence encoding
stabilized fusion of glutathione-S-transferase and human cystatin C, bla: Gene for ß-lactamase resistance, ori:
first base of the newly synthesized single strand, lacIq: Gene encoding the lac repressor.
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VIII.3.2 Plasmids for eukaryotic protein production
Figure 37: Maps of pMS-based plasmids
hCC: Sequence encoding human cystatin C, eGFP (=GFP): Sequence encoding enhanced green fluorescent
protein, SNAP: Sequence for mutant O6-alkylguanine-DNA alkyltransferase, Hinge-Fc: Sequence for the hinge-
region and fragment-crystallisable of an human antibody, IVS: “pIRES-EGFP-vector-derived synthetic intron”,
IRES: internal ribosomal entry site, BGH pA: bovine growth hormone polyadenylation sequence, f1 ori: origin
of replication, PSV40: SV40 promoter, SV40 pA: SV40 polyadenylation sequence, PEM-7: EM-7 promoter,
ZeoR: Zeocin resistance gene, PCMV: Cytomegalovirus promoter, T7: T7 promoter/priming site, nat: Native
secretion signal of hCC, L: Secretion signal from the V-J2-C region of the mouse Igκ, pMS: Plasmid Michael
Stoecker (Stoecker et al. 2003).
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VIII.4 Primer combinations used for hybridoma rescue
Table 21: Primer combinations used for the negative control in hybridoma rescue.
The GenBank accession numbers are given.
VH 5'-
primer
JH 3'-primer
VL 5'-
primers
JL Kappa 3'-primer
FM99
3421
FM99
3422
FM99
3423
FM99
3424
FM99
3425
FM99
3426
FM99
3427
FM99
3428
FM99
3429
Ne
gat
ive
 co
ntr
ols
 (n
o c
DN
A)
FM99
3421
FM99
3422
FM99
3423
FM99
3424
FM99
3425
FM99
3426
FM99
3427
FM99
3428
FM99
3429
FM993988-
FM993995 I
FM994031-
FM994045 VFM993996-
FM993997
FM994046-
FM994049
FM993998-
FM994001 II
FM994050-
FM994054 VIFM994002-
FM994005
FM994056-
FM994064
FM994006-
FM994013 III
FM994055,
FM994065-
FM994068 VII
FM994014-
FM994019
FM994069-
FM994072
FM994020-
FM994025 IV
FM994073-
FM994078 VIII
FM994026-
FM994030
FM994079-
FM994083 IX
Table 22: Primer combinations used for VH- and VL chain amplification in hybridoma rescue.
The GenBank accession numbers are given.
VH 5'-
primer
JH 3'-primer
VL 5'-
primers
JL Kappa 3'-primer
FM99
3421
FM99
3422
FM99
3423
FM99
3424
FM99
3425
FM99
3426
FM99
3427
FM99
3428
FM99
3429
Am
pli
fic
atio
n
FM993988-
FM993995 1 9 17 25
FM994031-
FM994045 1 9 17 25 33
FM993996-
FM993997 2 10 18 26
FM994046-
FM994049 2 10 18 26 34
FM993998-
FM994001 3 11 19 27
FM994050-
FM994054 3 11 19 27 35
FM994002-
FM994005 4 12 20 28
FM994056-
FM994064 4 12 20 28 36
FM994006-
FM994013 5 13 21 29
FM994055,
FM994065-
FM994068 5 13 21 29 37
FM994014-
FM994019 6 14 22 30
FM994069-
FM994072 6 14 22 30 38
FM994020-
FM994025 7 15 23 31
FM994073-
FM994078 7 15 23 31 39
FM994026-
FM994030 8 16 24 32
FM994079-
FM994083 8 16 24 32 40
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VIII.5 DNA sequences, CDRs and FRs determined for hCC-specific
antibody VH and VL
VIII.5.1 MAb CyDI-1
VIII.5.1.1 DNA sequence for mAb CyDI-1 VH
CAGGTCCAACTGCAGCAACCTGGGTCTGAGCTGGTGAGGCCTGGAGCTTCAGTGA
AGCTGTCCTGCAAGGCTTCTGGCTACACATTCACCACCTATTGGATGCACTGGGT
GAAGCAGAGGCCTGGACAAGGCCTTGAGTGGGTTGGAAATATTGATCCTGGTAG
TGGTAATACTAACTACGATGAGAAGTTCAAGAGAAAGGGCACACTGACTGTTGA
CACATCCTCCAGCACAGCCTACATGCACCTCAACAGCCTGACATCTGAGGACTCT
GCGGTCTATTACTGTACGGCGGGGTTTGACTACTGGGGCCAAGGCACCACTCTCA
CAGTCTCCTCA
VIII.5.1.2 DNA sequence for mAb CyDI-1 VL
GACATCCAGATGACACAGTCTCCATCCAGTCTGTCTGCATCCCTTGGAGACACAA
TTACCATCACTTGCCATGCCAGTCAGAACATTGATGTTTGGTTAGGCTGGTACCA
GCAGAAACCAGGAAATATTCCTAAACTGTTGATCTATCAGGCTTCCAACTTGCAC
ACAGGCGTCCCATCAAGGTTTGGTGGCAGTGGATCTGGAACATATTTCACATTAA
CCATCAGCAGCCTGCAGCCTGAAGACATGGCCACTTACTACTGTCAACAGGGTCA
AAGTTATCCGCTCACGTTCGGTGCTGGGACCAAGCTGGAGCTGAAACGT
VIII.5.1.3 CDRs and FRs for mAb CyDI-1 VH
VIII.5.1.4 CDRs and FRs for mAb CyDI-1 VL
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VIII.5.2 MAb CyDI-2
VIII.5.2.1 DNA sequence for mAb CyDI-2 VH
GAAGTGAAGCTTGAGGAGTCTGGAGGAGGCTTGGTGCAACCTGGAAGATCCATG
AAACTCTCCTGTGTTGCCTCTGGATTCACTTTCAGTAACTACTGGATGCACTGGTT
CCGCCAGTCTCCAGAGAAGGGGCTTGAGTGGGTTGCTGAAATTAGATTGAAATCT
AATAATTATGCAACACATTATGCGGACTCTGTGAAAGGGAGGTTCACCATCTCAC
GAGATGATTCCAAGAGTAGTGTCTACCTGCAAATGACCATCTTAAGAACTGAAGA
CTCTGGCATTTATTACTGTACGACTGGGAACTTTGACTACTGGGGCCAAGGCACC
ACTCTCACAGTCTCCTCA
VIII.5.2.2 DNA sequence for mAb CyDI-2 VL
GACATTGTGCTGACACAGTCTCCTGCTTCCTTAGCTGTATCTCTGGGGCAGAGGG
CCACCATCTCATGCAGGGCCAACAAAAGTGTCATTACATCTGGCTATAGTTATAT
GAACTGGTACCAACAGAAACCAGGACAGTCACCCAAACTCCTCATCTATCTTGCA
TCCAACCTAGAATCTGGGGTCCCTGCCAGGTTCAGTGGCAGTGGGTCTGGGACAG
ACTTCACCCTCAATATCCATCCTGTGGAGGAGGAGGATGCTGCAACGTATTACTG
TCAGCACAGTAGGGAGCTTCCGTACACGTTCGGAGGGGGGACCAAGCTGGAAAT
AAAACGT
VIII.5.2.3 CDRs and FRs for mAb CyDI-2 VH
VIII.5.2.4 CDRs and FRs for mAb CyDI-2 VL
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VIII.5.3 MAb CyDI-3
VIII.5.3.1 DNA sequence for mAb CyDI-3 VH
GAAGTGAAGCTTGAGGAGTCTGGAGGAGGCTTGGTGCAACCTGGAGGATCTATG
AAACTCTCCTGTGTTGCCTCTGGATTCACTTTCAGTAAGTACTGGATGCACTGGGT
CCGCCAGTCTCCAGAGAAGGGGCTTGAGTGGATTGCTGAAATCAGATTGAAATCT
AATAATTATGCAACACATTATGCGGAGTCTGTGAAAGGGAGGTTCACCATCTCAC
GAGATGATTCCAAAAGTAGTGTCTACCTGCAAATGAACAACTTAAGAACTGAAG
ACACTGGCATTTATTACTGTACGACTGGGAACTTTGACTACTGGGGCCAAGGCAC
CACTCTCACAGTCTCCTCAG
VIII.5.3.2 DNA sequence for mAb CyDI-3 VL
GACATTGTGCTAACACAGTCTCCTGCTTCCTTAGGTGCATCTCTGGGGCAGAGGG
CCACCATCTCATGCAGGGCCAGCAAAAGTGTCATTACATCCGGGCATAGTTATAT
GAACTGGTACCAACAGAAACCAGGACAGCCACCCAAACTCCTCATCTATCTTGCA
TCCAACCTAGAATCTGGGGTCCCTGCCAGGTTCAGTGGCAGTGGGTCTGGGACAG
ACTTCACCCTCAATATCCATCCTGTGGAGGAGGAGGATGCTGCAACCTATTACTG
TCAGCACAGTAGGGAGCTTCCGTACACGTTCGGAGGGGGGACCAAGCTGGAAAT
AAAACGT
VIII.5.3.3 CDRs and FRs for mAb CyDI-3 VH
VIII.5.3.4 CDRs and FRs for mAb CyDI-3 VL
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VIII.5.4 MAb CyDI-4
VIII.5.4.1 DNA sequence for mAb CyDI-4 VH
GAGGTGCAGCTGAAGGAGTCAGGACCTAGCCTCGTGAAACCTTCTCAGACTCTGT
CCCTCACCTGTTCTGTCACTGGCGACTCCATCACCAGTGGTTACTGGAACTGGATC
CGGAAATTCCCAGGGAATAAACTTGAGTACATGGGATATATAACCTACAGTGGTA
CCACTTACTACAATCCATCTCTCAAAAGTCGAATTTCCATCACTCGAGACACATCC
AAGAACCAGTACTACCTGCAGTTGAATTCTGTGACTACTGAGGACACAGCCACAT
ATTACTGTGCAAGCTTGGGGTTTGCTTACTGGGGCCAAGGGACTCTGGTCACTGT
CTCTGCA
VIII.5.4.2 DNA sequence for mAb CyDI-4 VL
GACATTGTGATGACCCAGTCTCCATCTTATCTTGCTGCATCTCCTGGAGAAACCAT
TACTATTAATTGCGGGGCGAGTAAGAGCATTAGCAAAAATTTAGCCTGGTATCAG
GAGAAACCTGGGAAAACTAATAAGCTTCTCATCTACTCTGGATCCACTTTGCAAT
CTGGAATTCCATCAAGGTTCAGTGGCAGTGGATCTGGTACAGATTTCACTCTCAC
CATCAGTAGCCTGGAGCCTGAGGATTTTGCAATGTATTACTGTCAACAGCATAAT
GAATACCCGTACACGTTCGGAGGGGGGACCAAGCTGGAAATAAAACGG
VIII.5.4.3 CDRs and FRs for mAb CyDI-4 VH
VIII.5.4.4 CDRs and FRs for mAb CyDI-4 VL
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VIII.6 Features of mAbs CyDI 1 to -4
Table 23: VH/VL, FR and CDR lengths of mAbs CyDI 1 to -4.
The amino acid lengths of VH/VL, FR and CDR were determined according to Dr. Andrew C.R. Martin's Group,
MacCallum et al. 1996 (I) and by IMGT (II).
I II
VH AA FR lengths CDR lengths FR lengths CDR lengths
CyDI-1 113 [25.14.32.11] [10.17.4] [25.17.38.11] [8.8.6]
CyDI-2 116 [25.14.32.11] [10.19.5] [25.17.38.11] [8.10.7]
CyDI-3 116 [25.14.32.11] [10.19.5] [25.17.38.11] [8.10.7]
CyDI-4 113 [25.14.32.11] [10.16.5] [25.17.38.11] [8.7.7]
VL AA FR lengths CDR lengths FR lengths CDR lengths
CyDI-1 108 [23.15.32.11] [11.7.9] [26.17.36.10] [6.3.9]
CyDI-2* 112 [23.15.32.11] [15.7.9] [26.17.36.10] [10.3.9]
CyDI-3 112 [23.15.32.11] [15.7.9] [26.17.36.10] [10.3.9]
CyDI-4 108 [23.15.32.11] [11.7.9] [26.17.36.10] [6.3.9]
AA: amino acids
*: Potential N-linked glycosylation sites
Table 24: Junction amino acid sequences and germlines of mAbs CyDI 1 to -4.
Junction amino acid sequences and germlines were determined by IMGT.
VH JUNCTION
(AA)
Germlines (GENE*allele)
V-GENE J-GENE D-GENE
CyDI-1 CTAGFDYW Musmus IGHV1S22*01 F Musmus IGHJ2*01 F (a) Musmus IGHD3-
1*01 F
CyDI-2 CTTGNFDY
W
Musmus IGHV6-6*02 F Musmus IGHJ2*01 F (a) Musmus IGHD4-
1*01 F
CyDI-3 CTTGNFDY
W
Musmus IGHV6-6*02 F Musmus IGHJ2*01 F (a) Musmus IGHD4-
1*01 F
CyDI-4 CASLGFAYW Musmus IGHV3-8*02 F Musmus IGHJ3*01 F Musmus IGHD3-
1*01 F
VL AA
JUNCTION
V-GENE J-GENE
CyDI-1 CQQGQSYPL
TF
Musmus IGKV15-103*01 Musmus IGKJ5*01 F
CyDI-2 CQHSRELPY
TF
Musmus IGKV3-12*01 F Musmus IGKJ2*01 F
CyDI-3 CQHSRELPY
TF
Musmus IGKV3-12*01 F Musmus IGKJ2*01 F
CyDI-4 CQQHNEYPY
TF
Musmus IGKV16-104*01 F Musmus IGKJ2*01 F
(a) Other possibilities: Musmus_IGHJ2*03 (shorter alignment but highest percentage of identity)
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Table 25: Sequence comparison of VH and VL domains of CyDI-1 to -4
VH (N- to C-terminal end)
CyDI-1: QVQLQQPGSELVRPGASVKLSCKASGYTFTTYWMHWVKQRPGQGLEWVGNIDPGSGNTN
CyDI-2: EVKLEESGGGLVQPGRSMKLSCVASGFTFSNYWMHWFRQSPEKGLEWVAEIRLKSNNYAT
CyDI-3: EVKLEESGGGLVQPGGSMKLSCVASGFTFSKYWMHWVRQSPEKGLEWIAEIRLKSNNYAT
CyDI-4: EVQLKESGPSLVKPSQTLSLTCSVTGDSITSGYWNWIRKFPGNKLEYMGYITYSGTTYYNPS
-YDEKFKRKGTLTVDTSSSTAYMHLNSLTSEDSAVYYCTAGFDYWGQGTTLTVSS
-HYADSVKGRFTISRDDSKSSVYLQMTILRTEDSGIYYCTTGNFDYWGQGTTLTVSS
-HYAESVKGRFTISRDDSKSSVYLQMNNLRTEDTGIYYCTTGNFDYWGQGTTLTVSS
-LKSRISITRDTSKNQYYLQLNSVTTEDTATYYCASLGFAYWGQGTLVTVSA
VL (N- to C-terminal end)
CyDI-1: DIQMTQSPSSLSASLGDTITITCHASQNIDVWLGWYQQKPGNIPKLLIYQASNLHTGVPSRFG
CyDI-2: DIVLTQSPASLAVSLGQRATISCRANKSVITSGYSYMNWYQQKPGQSPKLLIYLASNLESGV
CyDI-3: DIVLTQSPASLGASLGQRATISCRASKSVITSGHSYMNWYQQKPGQPPKLLIYLASNLESGV
CyDI-4: DIVMTQSPSYLAASPGETITINCGASKSISKNLAWYQEKPGKTNKLLIYSGSTLQSGIPSRFSG
-GSGSGTYFTLTISSLQPEDMATYYCQQGQSYPLTFGAGTKLELKR
-PARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRELPYTFGGGTKLEIKR
-PARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRELPYTFGGGTKLEIKR
-SGSGTDFTLTISSLEPEDFAMYYCQQHNEYPYTFGGGTKLEIKR
The differences between CyDI-2 and CyDI-3 are marked in red.
N: Potential N-linked glycosylation site (Kornfeld and Kornfeld 1985).
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VIII.7 List of abbreviations
°C Degree Celsius
% Percent
μg Microgram
μl Microliter
µm Micrometer
8OHdG 8-hydroxy-2′-deoxyguanosine
AA Amino acids
ABTS 2,2'-Azino-bis(3-ethylbenzthiazoline-6-sulphonic acid)
AEX Anion exchange chromatography
AP Alkaline phosphatase
Aβ Amyloid-β
BG O6-benzylguanine
BIOTRONIK BIOTRONIK SE & Co. KG
bp (s) Base pair/base pairs
BSA Bovine serum albumin
CaM Calmodulin
CEA Carcinoembryonic antigen
CDR Complementarity determining region
CKD Chronic kidney disease
CSF Cerebrospinal fluid
C-terminal Carboxy-terminal
cv Column volume (s)
CyDI Cystatin C-specific antibodies derived from the DiaImplant project
DAB 3,3′-Diaminobenzidine tablets
dATP Deoxyadenosine triphosphate
dCTP Deoxycytidine triphosphate
dGTP Deoxyguanosine triphosphate
DMSO Dimethyl sulfoxide
dNHuS hCC-depleted normal human serum
dTTP Deoxythymidine triphosphate
E. coli Escherichia coli
EA-SRID Enzyme-amplified single radial immunodiffusion
eGFR Estimated glomerular filtration rate
EIA Enzyme immunoassay
ELISA Enzyme-linked immunosorbent assay
FCS Fetal calf serum
VIII Appendix 104
fg Femtogram
FR Framework regions
Fraunhofer IME Fraunhofer Institute for Molecular Biology and Applied Ecology IME
Fraunhofer IMS Fraunhofer Institute for Microelectronic Circuits and Systems
FXa Factor Xa cleavage site
g Acceleration
GFP (=eGFP) Enhanced green fluorescent protein
GST Glutathione S-transferase
h Hour (s)
HC Heavy chain
hCC Human cystatin C
HER Human epidermal growth factor receptor
Hinge-Fc Hinge region with the crystallisable fragment of a human antibody
HRP Horse radish peroxidase
IgG Immunoglobulin gamma
IgG1:κ Immunoglobulin G1 and Igκ isotype
IgK Immunoglobulin kappa
IMAC Immobilized metal ion affinity chromatography (IMAC)
IMTEK University of Freiburg, Department of Microsystems Engineering
IRMM Institute for Reference Materials and Measurements
kDa Kilodalton
LC Light chain
M Molar
mA Miliampere
mAb(s) Monoclonal antibody (-ies)
MCS Multiple cloning site
min Minute (s)
mM Milimolar
MOS-FET Metal oxide semiconductor field-effect transistor
NBT/BCIP Nitro-blue tetrazolium/5-bromo-4-chloro-3'-indolyphosphate
ng Nanogram
NHS N-hydroxysuccinimide
NHuS Normal Human Serum
N-terminal Amino-terminal
PCR Polymerase chain reaction
PENIA Particle-enhanced nephelometric immunoassay
PETIA Particle-enhanced turbidimetric immunoassay
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pg Picogram
pI Isoelectric point
pmol Picomole
PSA Prostate specific antigen
RIA Radioimmunoassay
rpm Revolutions per minute
RU Response units
SDS Sodium dodecyl sulphate
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis
sELISA Sandwich ELISA
SNAP Mutant O6-alkylguanine-DNA alkyltransferase,
SOE Splicing by overlap extinction
SPIA Sol particle immunoassay
SPR Surface plasmon resonance spectroscopy analysis
StepPO Peroxidase-conjugated Streptavidin
TGF-β Transforming growth factor β
TR-FIA Time-resolved fluorescence immunoassay
V Voltage
VH Variable heavy
VL Variable light
VIII.8 List of figures
Figure 1: Structure of stabilized monomeric and wild-type dimeric hCC. ................................ 2
Figure 2: Schematic illustration of the in vivo detection principle for the biochip. ................. 11
Figure 3: Workflow of this PhD thesis..................................................................................... 12
Figure 4: Illustration of the generation of insert for cloning. ................................................... 35
Figure 5: GST and stGST-hCC prokaryotic expression cassettes............................................ 35
Figure 6: HCC, hCC-Hinge-Fc, hCC-SNAP and GFP-hCC eukaryotic expression cassettes. 36
Figure 7: Gel electrophoresis and immunoblot analysis of IMAC purified............................. 37
Figure 8: Gel electrophoresis and immunoblot analysis of produced proteins. ....................... 38
Figure 9: Hybridoma selection by indirect ELISA and sELISA analysis. ............................... 40
Figure 10: SPR spectroscopic analysis of selected monoclonal hybridoma supernatants using
hCC......................................................................................................................... 41
Figure 11: Gel electrophoresis and immunoblot analysis of a mAb CyDI-1-purification by
affinity chromatography. ........................................................................................ 43
VIII Appendix 106
Figure 12: Gel electrophoresis and immunoblot analysis of purified mAb CyDI-1, CyDI-4 and
CyDI-2.................................................................................................................... 43
Figure 13: SPR spectroscopic analysis of mAb CyDI-1 based on its ability to bind and release
hCC and hCC-fusion proteins. ............................................................................... 44
Figure 14: SPR spectroscopic analysis of mAb CyDI-2 based on its ability to bind and release
hCC and hCC-fusion proteins. ............................................................................... 45
Figure 15: SPR spectroscopic analysis of mAb CyDI-4 based on its ability to bind and release
hCC and hCC-fusion proteins. ............................................................................... 45
Figure 16: SPR spectroscopic analysis of kinetics for mAb CyDI-1 using hCC. .................... 46
Figure 17: Gel electrophoresis and immunoblot analysis of specificity of mAb CyDI-4 and
Cyst-13 for hCC and GFP-hCC.............................................................................. 47
Figure 18: Analysis of cross-reactivity of mAb CyDI-4 by sELISA and indirect ELISA....... 48
Figure 19: Thermo-stability analysis of mAb CyDI-4 by indirect ELISA and sELISA.......... 49
Figure 20: Simplified illustration of the preliminary two-well chip-based detection system.. 50
Figure 21: Analysis of a preliminary circuit for chip-based detection..................................... 51
Figure 22: Schematic overview of fluorescence-based replacement assays. ........................... 52
Figure 23: Bleaching analysis of GFP-hCC. ............................................................................ 53
Figure 24: Controls for the repetitive replacement assay......................................................... 54
Figure 25: Analysis of the repetitive replacement characteristics on mAb CyDI-4 using GFP-
hCC and hCC.......................................................................................................... 54
Figure 26: Analysis of the time-dependent replacement characteristics on mAb CyDI-4
replacing GFP-hCC with hCC................................................................................ 55
Figure 27: Analysis of the time-dependent replacement characteristics on mAb CyDI-4
replacing hCC with GFP-hCC................................................................................ 56
Figure 28: Dynamic range of time-dependent replacement. .................................................... 56
Figure 29: Replacement assay with reference material showing the assay in both directions. 57
Figure 30: Analysis of dNHuS by sELISA. ............................................................................. 58
Figure 31: Replacement assay with serial diluted reference material showing the mean of
assays...................................................................................................................... 59
Figure 32: Simplified illustration of the revised one-well chip-based detection system ......... 59
Figure 33: Gel electrophoresis analysis of coding sequences for mAb CyDI-2 VH and VL
chain. ...................................................................................................................... 61
Figure 34: “Comparison of leading cases of death over the past decade, 2000 and 2011”
(WHO 2013)........................................................................................................... 65
VIII Appendix 107
Figure 35: Synthetic gene coding for hCC with natural targeting sequence............................ 92
Figure 36: Maps of pGEX-based plasmids .............................................................................. 94
Figure 37: Maps of pMS-based plasmids................................................................................. 95
VIII.9 List of tables
Table 1: Used enzymes with the appropriate suppliers. ........................................................... 14
Table 2: Used reaction kits with the appropriate suppliers. ..................................................... 14
Table 3: Used matrices for protein purification with the appropriate suppliers....................... 14
Table 4: Used oligonucleotides and their applications............................................................. 15
Table 5: Used originating plasmids with the appropriate suppliers. ........................................ 15
Table 6: Used antibodies with the appropriate suppliers, the antibody working -/stock
concentration and their applications.......................................................................... 16
Table 7: Used substrates with the appropriate suppliers and the substrate application. .......... 16
Table 8: Composition of used media, buffers and solutions. ................................................... 17
Table 9: PCR master mix for one reaction using Taq DNA polymerase. ................................ 24
Table 10: PCR incubation scheme. .......................................................................................... 24
Table 11: Composition of 12%- and 15%-SDS-PAGE-gels, respectively. ............................. 27
Table 12: Indirect ELISA protocol........................................................................................... 29
Table 13: sELISA protocol. ..................................................................................................... 32
Table 14: Fluorescence-based replacement assay protocol...................................................... 33
Table 15: Protein yields of eukaryotically produced proteins after purification...................... 38
Table 16: Isotype of mAbs. ...................................................................................................... 42
Table 17: Primer combinations used for amplification of hCC-specific VH and VL chains. . 62
Table 18: SOE-PCR for cloning............................................................................................... 92
Table 19: Insert generation by PCR. ........................................................................................ 93
Table 20: In vivo amplification and cloning............................................................................. 93
Table 21: Primer combinations used for the negative control in hybridoma rescue. ............... 96
Table 22: Primer combinations used for VH- and VL chain amplification in hybridoma
rescue......................................................................................................................... 96
Table 23: VH/VL, FR and CDR lengths of mAbs CyDI 1 to -4............................................ 101
Table 24: Junction amino acid sequences and germlines of mAbs CyDI 1 to -4................... 101
Table 25: Sequence comparison of VH and VL chains of CyDI-1 to -4 ............................... 102
Acknowledgements
First of all I would like to thank Prof. Dr. Rainer Fischer for the great opportunity to carry
out my PhD thesis at the Fraunhofer IME (Aachen) and for supervising this PhD thesis.
Then, I would like to thank Prof. Dr. Dr. Stefan Barth for giving me the chance to work in
his department and for co-supervising me.
Thank you Prof. Dr. Bohrmann for agreeing to act as co-referent.
I also would like to thank Dr. Joerg Naehring for supervising me within the diagnostics-
group, for giving the right directions and for giving me working freedom. Thank you Joerg for
critically reading this PhD thesis and for all the discussions during the last three years. I
learned a lot.
My colleagues I would like to thank for the friendly atmosphere, the lively discussions and
the lot of fun. It was a pleasure to work with you all and being part of the Fraunhofer IME.
Special thanks go to Kai Fuhrmann and Severin Schmies for their technical assistance
within this project and Holger Spiegel for his help with the Biacore-data.
Stephanie Kapelski I would like to thank for critically reading this PhD thesis.
Finally, I would like to thank my family for their love, their support and their faith in me.
Without you this would not have been possible.
